<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" dtd-version="1.1" specific-use="sps-1.9" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ABC HF</journal-id>
<journal-title-group>
<journal-title>ABC: Heart Failure &#x26; Cardiomyopathy</journal-title>
<abbrev-journal-title abbrev-type="publisher">ABC Heart Fail Cardiomyop</abbrev-journal-title></journal-title-group>
<issn pub-type="epub">0000-0000</issn>
<publisher>
<publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">abchf.20210006</article-id>
<article-id pub-id-type="doi">10.36660/abchf.20210006</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Article</subject></subj-group></article-categories>
<title-group>
<article-title>Acute Inspiratory Muscle Training Modifies Hemodynamic Indices in Patients with Heart Failure with Preserved Ejection Fraction</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">0000-0001-8158-6151</contrib-id>
<name><surname>Menezes</surname><given-names>M&#xE1;rcio Garcia</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">0000-0002-8126-7211</contrib-id>
<name><surname>Garcia</surname><given-names>Eduardo Lima</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref> <xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">0000-0002-6327-1428</contrib-id>
<name><surname>Franzoni</surname><given-names>Leandro Tolfo</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref> <xref ref-type="aff" rid="aff3"><sup>3</sup></xref> <xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib>
<contrib contrib-type="author">
<name><surname>Grings</surname><given-names>Vanessa</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">0000-0002-5774-2780</contrib-id>
<name><surname>Danzmann</surname><given-names>Luiz Claudio</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref> <xref ref-type="aff" rid="aff2"><sup>2</sup></xref> <xref ref-type="corresp" rid="c1"/></contrib>
<aff id="aff1">
<label>1</label>
<institution content-type="orgname">Universidade Luterana do Brasil</institution>
<institution content-type="orgdiv1">Departamento de Cardiologia</institution>
<institution content-type="orgdiv2">Faculdade de Medicina</institution>
<addr-line>
<named-content content-type="city">Canoas</named-content>
<named-content content-type="state">RS</named-content></addr-line>
<country country="BR">Brazil</country>
<institution content-type="original">Departamento de Cardiologia, Faculdade de Medicina da Universidade Luterana do Brasil, Canoas, RS - Brazil</institution></aff>
<aff id="aff2">
<label>2</label>
<institution content-type="orgname">Pontif&#xED;cia Universidade Cat&#xF3;lica do Rio Grande do Sul PUCRS</institution>
<addr-line>
<named-content content-type="city">Porto Alegre</named-content>
<named-content content-type="state">RS</named-content></addr-line>
<country country="BR">Brazil</country>
<institution content-type="original">Hospital S&#xE3;o Lucas da Pontif&#xED;cia Universidade Cat&#xF3;lica do Rio Grande do Sul PUCRS, Porto Alegre, RS - Brazil</institution></aff>
<aff id="aff3">
<label>3</label>
<institution content-type="orgname">Hospital de Cl&#xED;nicas de Porto Alegre</institution>
<institution content-type="orgdiv1">Setor de Reabilita&#xE7;&#xE3;o Card&#xED;aca</institution>
<addr-line>
<named-content content-type="city">Porto Alegre</named-content>
<named-content content-type="state">RS</named-content></addr-line>
<country country="BR">Brazil</country>
<institution content-type="original">Setor de Reabilita&#xE7;&#xE3;o Card&#xED;aca, Hospital de Cl&#xED;nicas de Porto Alegre, Porto Alegre, RS - Brazil</institution></aff>
<aff id="aff4">
<label>4</label>
<institution content-type="orgname">Universidade Federal do Rio Grande do Sul</institution>
<addr-line>
<named-content content-type="city">Porto Alegre</named-content>
<named-content content-type="state">RS</named-content></addr-line>
<country country="BR">Brazil</country>
<institution content-type="original">Programa de P&#xF3;s-Gradua&#xE7;&#xE3;o em Ci&#xEA;ncias da Sa&#xFA;de: Cardiologia e Ci&#xEA;ncias Cardiovasculares da Universidade Federal do Rio Grande do Sul, Porto Alegre, RS - Brazil</institution></aff></contrib-group>
<author-notes>
<corresp id="c1"><bold>Mailing Address: Luiz Claudio Danzmann</bold> &#x2022; Rua Visconde do Herval, 472/903. Postal Code <postal-code>90130-150</postal-code>, Porto Alegre, RS - Brazil. E-mail <email>luiz.danzmann@ulbra.br</email></corresp>
<fn fn-type="con">
<p><bold>Author Contributions</bold></p>
<p>Conception and design of the research and Acquisition of data: Menezes MG, Garcia EL, Grings V, Danzmann LC; Analysis and interpretation of the data: Menezes MG, Grings V, Danzmann LC; Statistical analysis: Menezes MG, Franzoni LT, Danzmann LC; Obtaining financing: Menezes MG, Danzmann LC; Writing of the manuscript and Critical revision of the manuscript for intellectual content: Menezes MG, Garcia EL, Franzoni LT, Grings V, Danzmann LC.</p></fn>
<fn fn-type="conflict">
<p><bold>Potential Conflict of Interest</bold></p>
<p>No potential conflict of interest relevant to this article was reported.</p></fn></author-notes>
<pub-date publication-format="electronic" date-type="pub">
<day>06</day>
<month>07</month>
<year>2021</year></pub-date>
<pub-date publication-format="electronic" date-type="collection">
<season>Jul-Sep</season>
<year>2021</year></pub-date>
<volume>1</volume>
<issue>1</issue>
<fpage>27</fpage>
<lpage>32</lpage>
<history>
<date date-type="received">
<day>28</day>
<month>04</month>
<year>2021</year></date>
<date date-type="accepted">
<day>30</day>
<month>05</month>
<year>2021</year></date>
<date date-type="rev-recd">
<day>12</day>
<month>05</month>
<year>2021</year></date>
</history>
<permissions>
<license license-type="open-access" xml:lang="en" xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License</license-p></license></permissions>
<abstract>
<title>Abstract</title>
<sec>
<title>Background:</title>
<p>Heart failure with preserved ejection fraction (HFpEF), a syndrome associated to decrease functional capacity, is quite difficult to manage. Inspiratory muscle training (IMT) has been used to treat symptoms and to improve functional capacity of patients with HFpEF. Thus, we aimed to evaluate the immediate effects and after 1 h of IMT on arterial pulsatile hemodynamics and on hemodynamic indices of left ventricular filling derived from Doppler echocardiography in patients with HFpEF.</p>
</sec>
<sec>
<title>Methods:</title>
<p>Eighteen patients with HFpEF who underwent IMT at an intensity of 80% of maximum inspiratory pressure were evaluated by Doppler echocardiogram in the pre, post-immediate and post-late periods; furthermore, pulsatile hemodynamic variables were collected. Functional capacity was assessed using the 6-minute walk test.</p>
</sec>
<sec>
<title>Results:</title>
<p>The population was composed predominantly of women (66.7%), mean age of 61.3 (7.2) years. Modifications were observed in the non-invasive LV filling pressure index (E/e&#x2019;) (pre: 10.33 (SD, 3.15) vs post: 8.73 (SD, 2.24); p &#x3C; 0.001) and in the pulse wave velocity (pre: 8.33 (SD, 1.67) vs post: 7.63 (SD, 1.66) m/s; p &#x3C; 0.001), as well as pulse pressure (pre: 54.81 (SD, 18.73) vs post: 48.52 (SD, 15.74) mm Hg; p = 0.023).</p>
</sec>
<sec>
<title>Conclusion:</title>
<p>Our results demonstrated that a unique session of high-intensity IMT improved hemodynamic indices of LV filling and arterial stiffness in patients with HFpEF.</p>
</sec></abstract>
<kwd-group xml:lang="en">
<title>Keywords:</title>
<kwd>Heart Failure/physiopathology</kwd>
<kwd>Stroke Volume</kwd>
<kwd>Inspiratory Reserve Volume</kwd>
<kwd>Hemodynamic</kwd>
<kwd>Echocardiography/methods</kwd>
<kwd>Rehabilitation</kwd>
<kwd>Pulmonary Medicine</kwd>
<kwd>Respiratory System</kwd>
<kwd>Dyspnea</kwd></kwd-group>
<counts>
<fig-count count="6"/>
<table-count count="2"/>
<equation-count count="0"/>
<ref-count count="33"/>
<page-count count="6"/></counts></article-meta></front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome of greater prevalence in women, older adults, and patients with hypertension and diabetes.<xref ref-type="bibr" rid="B1"><sup>1</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B2"><sup>2</sup></xref> Its main mechanism of action is pathophysiological dysfunction in left ventricle (LV) filling. Such dysfunction can result in increased LV filling pressure, left atrial pressure, and pulmonary artery pressure, which can be altered at baseline or during exercise.<xref ref-type="bibr" rid="B3"><sup>3</sup></xref> Dyspnea and fatigue are common symptoms in patients with HFpEF, being one of the main causes of exercise intolerance.<xref ref-type="bibr" rid="B4"><sup>4</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B5"><sup>5</sup></xref></p>
<p>Central and peripheral arterial stiffness represents another important mechanism for HFpEF development. Altered pulsatile hemodynamic indices are associated with intolerance to effort, as they indicate worsening of ventriculo-arterial coupling, basically due to excessively increased LV afterload, hindering LV ejection performance.<xref ref-type="bibr" rid="B6"><sup>6</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B8"><sup>8</sup></xref></p>
<p>In addition to cardiovascular factors, respiratory muscles strength (RMS) has an additional role in global hemodynamic performance, influencing cardiac output, pulmonary pressure, and pulmonary arterial resistance, which contributes to activation of cardiovascular reflexes, limiting exercise tolerance in patients with HFpEF.<xref ref-type="bibr" rid="B9"><sup>9</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B12"><sup>12</sup></xref></p>
<p>Inspiratory muscle training (IMT) at moderate intensity (30% of maximal inspiratory pressure [MIP]) has already shown benefits in functional capacity and quality of life in patients with HFpEF.<xref ref-type="bibr" rid="B13"><sup>13</sup></xref> However, data about the effects of IMT on LV filling function and on behavior of arterial pulsatile hemodynamics have not been properly investigated, especially at intensities greater than 30% of MIP. Therefore, this study aimed to evaluate the immediate effect and after 1 h of IMT at 80% of MIP on LV diastolic function and arterial stiffness in patients with HFpEF.</p>
</sec>
<sec sec-type="methods">
<title>Methods</title>
<sec>
<title>Study design and population</title>
<p>This is a quasi-experimental cross-sectional study. Patients from a tertiary hospital in southern Brazil, aged over 45 years, who met the European Society of Cardiology criteria for HFpEF at the time the study was designed<xref ref-type="bibr" rid="B14"><sup>14</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B15"><sup>15</sup></xref> and who were clinically stable without previous hospitalization of 30 days were included. Patients with angina pectoris, atrial fibrillation, or atrial flutter during examination, pericardiopathies and musculoskeletal problems that prevented performance of functional capacity test were excluded.</p>
<p>After initial invitation, patients were informed about the echocardiogram to assess cardiac indexes and confirm the diagnosis; RMS assessment by MIP and maximal expiratory pressure (MEP); 6-minute walk test (6MWT); and assessment of arterial pulsatile hemodynamics. Patients who agreed to participate in the present study signed a free and informed consent form, according to the project approved by the ethics committee of the corresponding institution (39338614.0000.53.49).</p>
</sec>
</sec>
<sec>
<title>Variables evaluation</title>
<sec>
<title>Echocardiography</title>
<p>The evaluation of LV hemodynamic was performed by a 2-dimensional (2D) M-mode 10 standard Doppler echocardiogram (Siemens Acuson X 300, Siemens Medical Solutions USA Malvern, PA, USA) according to the recommendations of the American Society of Echocardiography.<xref ref-type="bibr" rid="B16"><sup>16</sup></xref> The echocardiograms were performed by the same operator. All echocardiographic recordings were obtained in digital format and recorded with an average of 3 cardiac cycles for analysis. The spectral Doppler recordings of mitral flow were obtained from the apical 4-chamber view to assess LV filling dynamics. The following variables were measured: peak early (E wave) and late (A wave) transmittal filling velocities in centimeters per second; E/A ratio; deceleration time of the E velocity in milliseconds (from the peak of E velocity to baseline). Spectral tissue Doppler was performed in the apical portion of the 4 chambers, the sample volume was set at 5 x 5 mm and placed at the junction of the LV septal and lateral wall with the mitral ring and 3 consecutive cardiac cycles, which were transferred to a workstation and analyzed. Peak velocities during systole, onset of diastole (E&#x2019;) and late diastole (a&#x2019;) were measured and the mean of both sites was analyzed. The non-invasive LV filling pressure index was assessed by early diastolic mitral inflow velocity and mitral annular tissue velocity ratio (E/e&#x2019;). The test was performed before RMS assessment, immediately after IMT (post-immediate), and 1 hour after IMT (post-late).</p>
</sec>
<sec>
<title>Arterial stiffness measured by pulse wave velocity</title>
<p>The assessment of arterial stiffness was performed by analyzing pulse wave velocity (PWV) and pulse pressure (PP) based on the oscillometric method, using data from the brachial artery pressure. The recordings were made at a diastolic pressure level for about 10 s using a conventional adult blood pressure cuff available in 2 sizes (24-34 and 32-42 cm) and a high accuracy pressure sensor (Mobil-O-Graph NG, IEM GmbH, Stolberg, Germany).<xref ref-type="bibr" rid="B17"><sup>17</sup></xref></p>
</sec>
<sec>
<title>Respiratory muscle strength test</title>
<p>RMS was always assessed by the same evaluator measuring MIP and MEP. Measurements were obtained using a pressure analyzer (Globalmed MVD300, Porto Alegre, Brazil). The procedures were repeated 6 times and the 3 greatest measures were considered valid, as long as the variation between them was not greater than 10%, following the guideline for pulmonary function tests.<xref ref-type="bibr" rid="B18"><sup>18</sup></xref> The patients were positioned seated, elbows supported, and a nasal clip was applied. The air passed through a nozzle transmitted the pressure level to the pressure transducer. MIP and MEP were considered to be the highest value of 3 measures selected.<xref ref-type="bibr" rid="B19"><sup>19</sup></xref> IMT intensity was determined by the highest value MIP (80%) for training protocol. The test was conducted after echocardiography and pulsatile hemodynamics.</p>
</sec>
<sec>
<title>Six-minute walk test</title>
<p>The 6MWT was always performed by the same evaluator according to recommendations by the American Thoracic Society.<xref ref-type="bibr" rid="B20"><sup>20</sup></xref> The test was conducted in an adapted corridor with markings of 30 meters. Patients were instructed to walk the longest distance possible over 6 minutes, always with encouragement. Pre-effort and post-effort blood pressures were checked, and heart rate was monitored during test.</p>
</sec>
</sec>
<sec>
<title>Intervention protocol</title>
<sec>
<title>Inspiratory muscle training</title>
<p>Individuals were submitted to an IMT session with an intensity of 80% of MIP. The PowerBreathe Classic light resistance model was used with intensity adjusted from 10 to 90 cm H<sub>2</sub>O. Three sets of 10 minutes were performed with recovery of 1 minute between each set. After IMT end, patients underwent echocardiogram and pulsatile hemodynamics evaluations again to assess immediate effects. In addition, they waited for 1 hour at rest to repeat the assessments.</p>
</sec>
</sec>
<sec>
<title>Statistical analysis</title>
<p>The variables were described in simple and relative frequency for categorical variables, and mean and standard deviation for continuous variables. To analyze the differences between continuous and categorical variables in the pre-, post-immediate, and post-late periods, the Generalized Estimation Equations method and Bonferroni correlation were used for multiple comparisons. For the sample calculation, expecting to reach a difference of 3.3 in the E/e&#x2019; index between pre- and post-protocol and considering a power of 80% and an alpha error of 5%, we estimated a sample of 18 participants. The data were analyzed using the SPSS version 18.0 statistical program.</p>
</sec>
<sec sec-type="results">
<title>Results</title>
<p>The study population consisted of 18 individuals with predominance of the female gender. The main associated comorbidities were systemic arterial hypertension, diabetes mellitus and obesity. In addition, drug therapy beta-blockers were the most used.</p>
<p>Despite the sample showed characteristic values for moderate diastolic dysfunction (E/e&#x2019;), the distance covered in 6MWT demonstrates a good functional capacity, representing absolute average by Weber&#x27;s class A individuals. In addition, PWV values appear to be within normal range for arterial stiffness, as well as cardiac output (3.94 (SD, 0.17) L/min) and cardiac index (2.05 (SD, 0.09) L/min/m<sup>2</sup>). However, PP values are high, identifying possible aortic stiffness with valve regurgitation. The baseline sample characteristics are described in <xref ref-type="table" rid="t1">Table 1</xref>.</p>
<table-wrap id="t1">
<label>Table 1</label>
<caption>
<title>Anthropometric, respiratory, echocardiographic, and hemodynamic characteristics</title></caption>
<table frame="hsides" rules="rows">
<colgroup width="50%">
<col/>
<col/></colgroup>
<thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000">
<tr>
<th align="left" valign="middle">Variables (N = 18)</th>
<th align="center" valign="middle">Values (mean (SD) or %)</th></tr></thead>
<tbody style="border-bottom: thin solid; border-color: #000000">
<tr>
<td align="left" valign="middle"><bold>Anthropometric data</bold></td>
<td align="center" valign="middle"/></tr>
<tr>
<td align="left" valign="middle">Age (years)</td>
<td align="center" valign="middle">61.3 (7.2)</td></tr>
<tr>
<td align="left" valign="middle">Height (cm)</td>
<td align="center" valign="middle">160 (0.9)</td></tr>
<tr>
<td align="left" valign="middle">Body mass (kg)</td>
<td align="center" valign="middle">84.1 (16.4)</td></tr>
<tr>
<td align="left" valign="middle">BMI (kg/m<sup>2</sup>)</td>
<td align="center" valign="middle">32 (4.6)</td></tr>
<tr>
<td align="left" valign="middle">Female (%)</td>
<td align="center" valign="middle">66.7</td></tr>
<tr>
<td align="left" valign="middle"><bold>Drug therapy (%)</bold></td>
<td align="center" valign="middle"/></tr>
<tr>
<td align="left" valign="middle">Beta-blocker</td>
<td align="center" valign="middle">76.5</td></tr>
<tr>
<td align="left" valign="middle">ACEi</td>
<td align="center" valign="middle">47.1</td></tr>
<tr>
<td align="left" valign="middle">ARB</td>
<td align="center" valign="middle">35.3</td></tr>
<tr>
<td align="left" valign="middle">CCB</td>
<td align="center" valign="middle">41.2</td></tr>
<tr>
<td align="left" valign="middle">Furosemide</td>
<td align="center" valign="middle">41.2</td></tr>
<tr>
<td align="left" valign="middle">Thiazide</td>
<td align="center" valign="middle">52.9</td></tr>
<tr>
<td align="left" valign="middle">ARA</td>
<td align="center" valign="middle">29.4</td></tr>
<tr>
<td align="left" valign="middle">Nitrate</td>
<td align="center" valign="middle">23.5</td></tr>
<tr>
<td align="left" valign="middle">Hydralazine</td>
<td align="center" valign="middle">11,8</td></tr>
<tr>
<td align="left" valign="middle">Antiplatelet</td>
<td align="center" valign="middle">52.9</td></tr>
<tr>
<td align="left" valign="middle"><bold>Comorbidities (%)</bold></td>
<td align="center" valign="middle"/></tr>
<tr>
<td align="left" valign="middle">Systemic hypertension</td>
<td align="center" valign="middle">94.1</td></tr>
<tr>
<td align="left" valign="middle">Diabetes</td>
<td align="center" valign="middle">41.2</td></tr>
<tr>
<td align="left" valign="middle">Obesity</td>
<td align="center" valign="middle">47.1</td></tr>
<tr>
<td align="left" valign="middle">Smoking</td>
<td align="center" valign="middle">5.9</td></tr>
<tr>
<td align="left" valign="middle">Coronary artery disease</td>
<td align="center" valign="middle">35.3</td></tr>
<tr>
<td align="left" valign="middle">Chronic obstructive pulmonary disease</td>
<td align="center" valign="middle">5.9</td></tr>
<tr>
<td align="left" valign="middle">Renal failure</td>
<td align="center" valign="middle">7.3</td></tr>
<tr>
<td align="left" valign="middle">Stroke</td>
<td align="center" valign="middle">4.7</td></tr>
<tr>
<td align="left" valign="middle">Rheumatic disease</td>
<td align="center" valign="middle">6.8</td></tr>
<tr>
<td align="left" valign="middle"><bold>Functional capacity</bold></td>
<td align="center" valign="middle"/></tr>
<tr>
<td align="left" valign="middle">NYHA I &#x2013; II (%)</td>
<td align="center" valign="middle">94.4</td></tr>
<tr>
<td align="left" valign="middle">NYHA III (%)</td>
<td align="center" valign="middle">5.6</td></tr>
<tr>
<td align="left" valign="middle">6MWT (meters)</td>
<td align="center" valign="middle">431.4 (117.2)</td></tr>
<tr>
<td align="left" valign="middle"><bold>Respiratory variables</bold></td>
<td align="center" valign="middle"/></tr>
<tr>
<td align="left" valign="middle">MIP (cm H<sub>2</sub>O)</td>
<td align="center" valign="middle">73.6 (17.8)</td></tr>
<tr>
<td align="left" valign="middle">Predicted MIP (cm H<sub>2</sub>O)</td>
<td align="center" valign="middle">115.8 (6.9)</td></tr>
<tr>
<td align="left" valign="middle">70% of predicted MIP (cm H<sub>2</sub>O)</td>
<td align="center" valign="middle">80.8 (4.9)</td></tr>
<tr>
<td align="left" valign="middle">MEP (cm H<sub>2</sub>O)</td>
<td align="center" valign="middle">124 (28.9)</td></tr>
<tr>
<td align="left" valign="middle">Predicted MEP (cm H<sub>2</sub>O)</td>
<td align="center" valign="middle">90.8 (19)</td></tr>
<tr>
<td align="left" valign="middle">70% of predicted MEP (cm H<sub>2</sub>O)</td>
<td align="center" valign="middle">65.6 (14.8)</td></tr>
<tr>
<td align="left" valign="middle">Inspiratory weakness (%)</td>
<td align="center" valign="middle">61.1</td></tr>
<tr>
<td align="left" valign="middle"><bold>Echocardiographic variables</bold></td>
<td align="center" valign="middle"/></tr>
<tr>
<td align="left" valign="middle">Simpson EF (%)</td>
<td align="center" valign="middle">64.2 (11.7)</td></tr>
<tr>
<td align="left" valign="middle">E/e&#x27;</td>
<td align="center" valign="middle">9.8 (3.6)</td></tr>
<tr>
<td align="left" valign="middle">E/A</td>
<td align="center" valign="middle">1 (0.7)</td></tr>
<tr>
<td align="left" valign="middle">IRT</td>
<td align="center" valign="middle">103.8 (87)</td></tr>
<tr>
<td align="left" valign="middle">LAV</td>
<td align="center" valign="middle">73.7 (25.7)</td></tr>
<tr>
<td align="left" valign="middle">iLAV</td>
<td align="center" valign="middle">39.4 (10.2)</td></tr>
<tr>
<td align="left" valign="middle">Teicholz iLVM (g/m&#xB2;)</td>
<td align="center" valign="middle">119.4 (47.3)</td></tr>
<tr>
<td align="left" valign="middle"><bold>Pulsatile hemodynamics variables</bold></td>
<td align="center" valign="middle"/></tr>
<tr>
<td align="left" valign="middle">PWV (m/s)</td>
<td align="center" valign="middle">8.3 (1.7)</td></tr>
<tr>
<td align="left" valign="middle">CPP</td>
<td align="center" valign="middle">54.8 (4.3)</td></tr>
<tr>
<td align="left" valign="middle">Aix</td>
<td align="center" valign="middle">32.2 (12.8)</td></tr></tbody></table>
<table-wrap-foot>
<fn id="TFN1">
<p><italic>BMI: body mass index; ACEi: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; CCB: calcium channel blocker; ARA: angiotensin receptor antagonists; NYHA: New York Heart Association; 6MWT: 6-minute walk test; MIP: maximal inspiratory pressure; MEP: maximal expiratory pressure; EF: ejection fraction; IRT: isovolumetric relaxation time; E: peak E-wave velocity; e&#x2019;: peak early diastolic velocity on tissue Doppler; LAV: left atrial volume; iLAV: indexed left atrial volume; iLVM: indexed left ventricular mass; PWV: pulse wave velocity; CPP: central pulse pressure; Aix: augmentation index.</italic></p></fn></table-wrap-foot></table-wrap>
<p>After 1 h of IMT, a significant change in E/e&#x2019; was observed compared to the initial values (10.33 (SD, 3.15) vs 8.73 (SD, 2.24); p &#x3C; 0.001) and also a reduction between the post-immediate and the post-late periods (10.38 (SD, 3.23) m/s vs 8.73 (SD, 2.24) m/s; p &#x3C; 0.011) (<xref ref-type="fig" rid="f1">Figure 1</xref>).</p>
<fig id="f1">
<label>Figure 1</label>
<caption>
<title>Estimation of left ventricle filling pressure pre, post-immediate and post-late. * p &#x3C; 0.05 between pre- and post-immediate; # p &#x3C; 0.05 between post-immediate and post-late. E/e&#x2019;: non-invasive index of LV filling.</title></caption>
<graphic xlink:href="0000-0000-abchf-001-01-0027-gf01.tif"/></fig>
<p>In relation to arterial stiffness, there were significant changes in PWV between pre- and post-late periods (8.33 (SD, 1.67) vs 7.63 (SD, 1.66) m/s; p &#x3C; 0.001) and between post-immediate and post-late periods (8.24 (SD, 1.78) vs 7.63 (SD, 1.66) m/s; p &#x3C; 0.001) (<xref ref-type="fig" rid="f2">Figure 2</xref>). Similarly, PP showed significant changes between pre- and post-late periods (54.81 (SD, 18.73) mm Hg vs 48.52 (SD, 15.74) mm Hg; p &#x3C; 0.001) and between post-immediate and post-late periods (57.92 (SD, 16.21) mm Hg vs 48.52 (SD, 15.68) mm Hg; p &#x3C; 0.001) (<xref ref-type="fig" rid="f3">Figure 3</xref>).</p>
<fig id="f2">
<label>Figure 2</label>
<caption>
<title>Pulse wave velocity pre, post-immediate and post-late. * p &#x3C; 0.05 between pre- and post-immediate; # p &#x3C; 0.05 between post-immediate and post-late.</title></caption>
<graphic xlink:href="0000-0000-abchf-001-01-0027-gf02.tif"/></fig>
<fig id="f3">
<label>Figure 3</label>
<caption>
<title>Pulse pressure pre, post-immediate and post-late. * p &#x3C; 0.05 between pre- and post-immediate; # p &#x3C; 0.05 between post-immediate and post-late.</title></caption>
<graphic xlink:href="0000-0000-abchf-001-01-0027-gf03.tif"/></fig>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>The present study evaluated the immediate effect and 1 hour after IMT on hemodynamic indexes of LV filling, as well as on pulsatile arterial hemodynamic indexes in patients with HFpEF. The main finding of the present study was that IMT modified hemodynamic indexes of LV filling and pulsatile hemodynamics, demonstrating the positive effects of high-intensity training.</p>
<p>There was a significant effect immediately after IMT for E/e&#x2019; ratio. We also found a significant effect from the post-immediate to the post-late. These results confirm our hypothesis that IMT would promote positive effects on hemodynamic indexes of LV filling. Some evidences suggest that IMT is effective in modifying E/e&#x2019; ratio; however, when performed at an intensity of 30%.<xref ref-type="bibr" rid="B13"><sup>13</sup></xref> Contrary to the literature, we demonstrated that high-intensity IMT (80% of MIP) is able to modify hemodynamic indexes of LV filling. In addition, it is noteworthy that we conducted only 1 supervised IMT session. We believe that maintaining high-intensity IMT for weeks can promote adequate mechanical action in the respiratory muscles, facilitating the redirection of peripheral blood flow, which can generate a stimulus in the bioavailability of nitric oxide and consequently in vasodilation.<xref ref-type="bibr" rid="B21"><sup>21</sup></xref></p>
<p>With regard to PWV, we found significant differences in comparison between post-immediate and post-late periods. PWV is an important predictor of cardiovascular disease and mortality.<xref ref-type="bibr" rid="B22"><sup>22</sup></xref> In addition, studies show that PWV is directly related to amendment to ventriculo-arterial coupling leading to exercise intolerance and causing hemodynamic changes in the afterload, with consequent increase in dyspnea to small and moderate efforts.<xref ref-type="bibr" rid="B10"><sup>10</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B12"><sup>12</sup></xref> Although PWV values are within normal range in our sample, PP is high, identifying possible aortic stiffness and valve regurgitation for these patients. Evidence indicates that a value of 50 mm Hg for PP is related to ventricular hypertrophy and mortality from cardiovascular diseases.<xref ref-type="bibr" rid="B23"><sup>23</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref> In the present study, we were able to demonstrate that there was a significant reduction in PP immediately after a high-intensity IMT session (p = 0.023).</p>
<p>Another important result that we found in the present study was that 61.1% of the sample presented respiratory muscle weakness, with a cutoff point of &#x3C; 80 cm H<sub>2</sub>0 for MIP.<xref ref-type="bibr" rid="B19"><sup>19</sup></xref> We know that BMI &#x3E; 30 kg/m<sup>2</sup> found for the present individuals is directly related to reductions in MIP, due to distension of diaphragm muscle fibers caused by the mechanical action of abdominal fat.<xref ref-type="bibr" rid="B25"><sup>25</sup></xref> A lower BMI is also associated with greater resistance of the respiratory muscles, demonstrating that the reduction of body mass is fundamental for these patients.<xref ref-type="bibr" rid="B26"><sup>26</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B27"><sup>27</sup></xref></p>
<p>It is important to reduce the hemodynamic indexes values of LV filling, arterial stiffness and PP, as well as to increase MIP in patients with HFpEF, since all these factors are integrated for the onset of dyspnea and fatigue during efforts.<xref ref-type="bibr" rid="B9"><sup>9</sup></xref> The reduced performance of this integrative system related to dyspnea and fatigue can be explained by abnormal chemoreflex activity, thus resulting in greater ventilation and greater sympathetic activity, hindering arterial baroreflex adjustments and increasing the time of adrenergic vasoconstriction, which results in increased right ventricular afterload.<xref ref-type="bibr" rid="B11"><sup>11</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B28"><sup>28</sup></xref> This inadequate hyperventilation during exercise modulates the chemoreflex activity due to a higher production of CO<sub>2</sub>, making peripheral O<sub>2</sub> extraction difficult and causing inefficiency of metabolic buffer, thus being able to increase neurohumoral activity.<xref ref-type="bibr" rid="B29"><sup>29</sup></xref> Finally, we can affirm that the metaboreflex activity of the respiratory muscles also influences ventilatory response and exercise intolerance in patients with HFpEF. This metaboreflex overload leads to increased phrenic nerve, ventilation, and sympathetic activity, consequently increasing vasoconstriction and fatigue of peripheral muscles.<xref ref-type="bibr" rid="B30"><sup>30</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B31"><sup>31</sup></xref></p>
<p>Therefore, the integration processes related to dyspnea and fatigue can directly influence myocardial work and blood flow redistribution.<xref ref-type="bibr" rid="B29"><sup>29</sup></xref> IMT has the potential to rehabilitate patients with HFpEF, and the rationale is related to improving venous return, increasing cardiac output, reducing ventricular afterload regardless of training mode.<xref ref-type="bibr" rid="B11"><sup>11</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B28"><sup>28</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B32"><sup>32</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B33"><sup>33</sup></xref> In addition, IMT can improve functional capacity and consequently promote a better quality of life for patients with HFpEF, since dyspnea and fatigue are associated with a worse prognosis.</p>
<p>The results of the present study are important to promote new questions about the intensity of IMT, since only 1 session with 80% of MIP promoted significant improvements in hemodynamic indices of LV filling and arterial stiffness, without complications during the protocol. Therefore, our results demonstrate that a high-intensity IMT session is effective for improving the parameters evaluated in patients with HFpEF. Nevertheless, it is worth mentioning that high-intensity IMT seems to be a promising strategy in the rehabilitation scenario.</p>
</sec>
<sec>
<title>Limitations</title>
<p>The present study has some limitations, among which we can mention the absence of a control group, which would add important information about the effects of IMT. Another limitation is that only 1 IMT session was conducted, causing a gap in the literature on the chronic effects of high-intensity IMT. Finally, we emphasize the importance of research in the area of IMT for patients with HFpEF. Here, we suggest that future studies assess the effects of different intensities of IMT with comparisons to a control group.</p>
</sec>
<sec sec-type="conclusions">
<title>Conclusion</title>
<p>Our results demonstrated that a unique session of high-intensity IMT improved hemodynamic indices of LV filling and arterial stiffness in patients with HFpEF. Future studies should test high-intensity IMT consecutive sessions as a rehabilitation method for patients with HFpEF.</p>
</sec></body>
<back>
<fn-group>
<fn fn-type="other" id="fn1">
<p><bold>Ethics approval and consent to participate</bold></p>
<p>This study was approved by the Ethics Committee of the Universidade Luterana do Brasil under the protocol number 393386.14.1.0000.5349. All the procedures in this study were in accordance with the 1975 Helsinki Declaration, updated in 2013. Informed consent was obtained from all participants included in the study.</p></fn>
<fn fn-type="supported-by" id="fn2">
<p><bold>Sources of Funding</bold></p>
<p>There were no external funding sources for this study.</p></fn>
<fn fn-type="other" id="fn3">
<p><bold>Study Association</bold></p>
<p>This study is not associated with any thesis or dissertation work.</p></fn></fn-group>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Owan</surname><given-names>TE</given-names></name>
<name><surname>Hodge</surname><given-names>DO</given-names></name>
<name><surname>Herges</surname><given-names>RM</given-names></name>
<name><surname>Jacobsen</surname><given-names>SJ</given-names></name>
<name><surname>Roger</surname><given-names>VL</given-names></name>
<name><surname>Redfield</surname><given-names>MM</given-names></name></person-group>
<article-title>Trends in prevalence and outcome of heart failure with preserved ejection fraction</article-title>
<source>N Engl J Med</source>
<year>2006</year>
<volume>355</volume>
<issue>3</issue>
<fpage>251</fpage>
<lpage>259</lpage></element-citation>
<mixed-citation>1. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355(3):251-9.</mixed-citation></ref>
<ref id="B2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lam</surname><given-names>CS</given-names></name>
<name><surname>Donal</surname><given-names>E</given-names></name>
<name><surname>Kraigher-Krainer</surname><given-names>E</given-names></name>
<name><surname>Vasan</surname><given-names>RS</given-names></name></person-group>
<article-title>Epidemiology and clinical course of heart failure with preserved ejection fraction</article-title>
<source>Eur Heart J. Fail</source>
<year>2011</year>
<volume>13</volume>
<issue>1</issue>
<fpage>18</fpage>
<lpage>28</lpage></element-citation>
<mixed-citation>2. Lam CS, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur Heart J. Fail. 2011;13(1):18-28.</mixed-citation></ref>
<ref id="B3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Borlaug</surname><given-names>BA</given-names></name>
<name><surname>Paulus</surname><given-names>WJ</given-names></name></person-group>
<article-title>Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment</article-title>
<source>Eur Heart J</source>
<year>2011</year>
<volume>32</volume>
<issue>6</issue>
<fpage>670</fpage>
<lpage>679</lpage></element-citation>
<mixed-citation>3. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J.. 2011;32(6):670-9.</mixed-citation></ref>
<ref id="B4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hristovski</surname><given-names>Z</given-names></name>
<name><surname>Projevska-Donegati</surname><given-names>D</given-names></name>
<name><surname>Georgievska-Ismail</surname><given-names>L</given-names></name></person-group>
<article-title>Echocardiographic predictors of chronotropic incompetence to exercise in patients with heart failure with preserved ejection fraction</article-title>
<source>Prilozi (Makedonska akademija na naukite i umetnostite Oddelenie za medicinski nauki)</source>
<year>2014</year>
<volume>35</volume>
<issue>2</issue>
<fpage>137</fpage>
<lpage>145</lpage></element-citation>
<mixed-citation>4. Hristovski Z, Projevska-Donegati D, Georgievska-Ismail L. Echocardiographic predictors of chronotropic incompetence to exercise in patients with heart failure with preserved ejection fraction. Prilozi (Makedonska akademija na naukite i umetnostite Oddelenie za medicinski nauki). 2014;35(2):137-45.</mixed-citation></ref>
<ref id="B5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kitzman</surname><given-names>DW</given-names></name>
<name><surname>Groban</surname><given-names>L</given-names></name></person-group>
<article-title>Exercise intolerance</article-title>
<source>Cardiol Clin</source>
<year>2011</year>
<volume>29</volume>
<issue>3</issue>
<fpage>461</fpage>
<lpage>477</lpage></element-citation>
<mixed-citation>5. Kitzman DW, Groban L. Exercise intolerance. Cardiol Clin. 2011;29(3):461-77.</mixed-citation></ref>
<ref id="B6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Tartiere-Kesri</surname><given-names>L</given-names></name>
<name><surname>Tartiere</surname><given-names>JM</given-names></name>
<name><surname>Logeart</surname><given-names>D</given-names></name>
<name><surname>Beauvais</surname><given-names>F</given-names></name>
<name><surname>Cohen Solal</surname><given-names>A</given-names></name></person-group>
<article-title>Increased proximal arterial stiffness and cardiac response with moderate exercise in patients with heart failure and preserved ejection fraction</article-title>
<source>J Am Coll Cardiol</source>
<year>2012</year>
<volume>59</volume>
<issue>5</issue>
<fpage>455</fpage>
<lpage>461</lpage></element-citation>
<mixed-citation>6. Tartiere-Kesri L, Tartiere JM, Logeart D, Beauvais F, Cohen Solal A. Increased proximal arterial stiffness and cardiac response with moderate exercise in patients with heart failure and preserved ejection fraction. J Am Coll Cardiol.2012;59(5):455-61.</mixed-citation></ref>
<ref id="B7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zile</surname><given-names>MR</given-names></name>
<name><surname>Baicu</surname><given-names>CF</given-names></name>
<name><surname>Gaasch</surname><given-names>WH</given-names></name></person-group>
<article-title>Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle</article-title>
<source>N Engl J med</source>
<year>2004</year>
<volume>350</volume>
<issue>19</issue>
<fpage>1953</fpage>
<lpage>1959</lpage></element-citation>
<mixed-citation>7. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J med. 2004;350(19):1953-9.</mixed-citation></ref>
<ref id="B8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kitzman</surname><given-names>DW</given-names></name>
<name><surname>Herrington</surname><given-names>DM</given-names></name>
<name><surname>Brubaker</surname><given-names>PH</given-names></name>
<name><surname>Moore</surname><given-names>JB</given-names></name>
<name><surname>Eggebeen</surname><given-names>J</given-names></name>
<name><surname>Haykowsky</surname><given-names>MJ</given-names></name></person-group>
<article-title>Carotid arterial stiffness and its relationship to exercise intolerance in older patients with heart failure and preserved ejection fraction</article-title>
<source>Hypertension. 1979)</source>
<year>2013</year>
<volume>61</volume>
<issue>1</issue>
<fpage>112</fpage>
<lpage>119</lpage></element-citation>
<mixed-citation>8. Kitzman DW, Herrington DM, Brubaker PH, Moore JB, Eggebeen J, Haykowsky MJ. Carotid arterial stiffness and its relationship to exercise intolerance in older patients with heart failure and preserved ejection fraction. Hypertension. 1979). 2013;61(1):112-9.</mixed-citation></ref>
<ref id="B9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lavietes</surname><given-names>MH</given-names></name>
<name><surname>Gerula</surname><given-names>CM</given-names></name>
<name><surname>Fless</surname><given-names>KG</given-names></name>
<name><surname>Cherniack</surname><given-names>NS</given-names></name>
<name><surname>Arora</surname><given-names>RR</given-names></name></person-group>
<article-title>Inspiratory muscle weakness in diastolic dysfunction</article-title>
<source>Chest</source>
<year>2004</year>
<volume>126</volume>
<issue>3</issue>
<fpage>838</fpage>
<lpage>844</lpage></element-citation>
<mixed-citation>9. Lavietes MH, Gerula CM, Fless KG, Cherniack NS, Arora RR. Inspiratory muscle weakness in diastolic dysfunction. Chest. 2004;126(3):838-44.</mixed-citation></ref>
<ref id="B10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ribeiro</surname><given-names>JP</given-names></name>
<name><surname>Chiappa</surname><given-names>GR</given-names></name>
<name><surname>Neder</surname><given-names>JA</given-names></name>
<name><surname>Frankenstein</surname><given-names>L</given-names></name></person-group>
<article-title>Respiratory muscle function and exercise intolerance in heart failure</article-title>
<source>Curr Heart Fail Rep</source>
<year>2009</year>
<volume>6</volume>
<issue>2</issue>
<fpage>95</fpage>
<lpage>101</lpage></element-citation>
<mixed-citation>10. Ribeiro JP, Chiappa GR, Neder JA, Frankenstein L. Respiratory muscle function and exercise intolerance in heart failure. Curr Heart Fail Rep. 2009;6(2):95-101.</mixed-citation></ref>
<ref id="B11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ribeiro</surname><given-names>JP</given-names></name>
<name><surname>Chiappa</surname><given-names>GR</given-names></name>
<name><surname>Callegaro</surname><given-names>CC</given-names></name></person-group>
<article-title>The contribution of inspiratory muscles function to exercise limitation in heart failure: pathophysiological mechanisms</article-title>
<source>R ev Bras Fisioter</source>
<year>2012</year>
<volume>16</volume>
<issue>4</issue>
<fpage>261</fpage>
<lpage>267</lpage></element-citation>
<mixed-citation>11. Ribeiro JP, Chiappa GR, Callegaro CC. The contribution of inspiratory muscles function to exercise limitation in heart failure: pathophysiological mechanisms. R ev Bras Fisioter. 2012;16(4):261-7.</mixed-citation></ref>
<ref id="B12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Meyer</surname><given-names>FJ</given-names></name>
<name><surname>Borst</surname><given-names>MM</given-names></name>
<name><surname>Zugck</surname><given-names>C</given-names></name>
<name><surname>Kirschke</surname><given-names>A</given-names></name>
<name><surname>Schellberg</surname><given-names>D</given-names></name>
<name><surname>Kubler</surname><given-names>W</given-names></name>
<etal/></person-group>
<article-title>Respiratory muscle dysfunction in congestive heart failure: clinical correlation and prognostic significance</article-title>
<source>Circulation</source>
<year>2001</year>
<volume>103</volume>
<issue>17</issue>
<fpage>2153</fpage>
<lpage>2158</lpage></element-citation>
<mixed-citation>12. Meyer FJ, Borst MM, Zugck C, Kirschke A, Schellberg D, Kubler W, et al. Respiratory muscle dysfunction in congestive heart failure: clinical correlation and prognostic significance. Circulation. 2001;103(17):2153-8.</mixed-citation></ref>
<ref id="B13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Palau</surname><given-names>P</given-names></name>
<name><surname>Dominguez</surname><given-names>E</given-names></name>
<name><surname>Nunez</surname><given-names>E</given-names></name>
<name><surname>Schmid</surname><given-names>JP</given-names></name>
<name><surname>Vergara</surname><given-names>P</given-names></name>
<name><surname>Ramon</surname><given-names>JM</given-names></name>
<etal/></person-group>
<article-title>Effects of inspiratory muscle training in patients with heart failure with preserved ejection fraction</article-title>
<source>Eur Heart J Prev Cardiol</source>
<year>2014</year>
<volume>21</volume>
<issue>12</issue>
<fpage>1465</fpage>
<lpage>1473</lpage></element-citation>
<mixed-citation>13. Palau P, Dominguez E, Nunez E, Schmid JP, Vergara P, Ramon JM, et al. Effects of inspiratory muscle training in patients with heart failure with preserved ejection fraction. Eur Heart J Prev Cardiol. 2014;21(12):1465-73.</mixed-citation></ref>
<ref id="B14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Benjamin</surname><given-names>EJ</given-names></name>
<name><surname>D&#x2019;Agostino</surname><given-names>RB</given-names></name>
<name><surname>Belanger</surname><given-names>AJ</given-names></name>
<name><surname>Wolf</surname><given-names>PA</given-names></name>
<name><surname>Levy</surname><given-names>D</given-names></name></person-group>
<article-title>Left atrial size and the risk of stroke and death. The Framingham Heart Study</article-title>
<source>Circulation</source>
<year>1995</year>
<volume>92</volume>
<issue>4</issue>
<fpage>835</fpage>
<lpage>841</lpage></element-citation>
<mixed-citation>14. Benjamin EJ, D&#x2019;Agostino RB, Belanger AJ, Wolf PA, Levy D. Left atrial size and the risk of stroke and death. The Framingham Heart Study. Circulation. 1995;92(4):835-41.</mixed-citation></ref>
<ref id="B15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Paulus</surname><given-names>WJ</given-names></name>
<name><surname>Tschope</surname><given-names>C</given-names></name>
<name><surname>Sanderson</surname><given-names>JE</given-names></name>
<name><surname>Rusconi</surname><given-names>C</given-names></name>
<name><surname>Flachskampf</surname><given-names>FA</given-names></name>
<name><surname>Rademakers</surname><given-names>FE</given-names></name>
<etal/></person-group>
<article-title>How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology</article-title>
<source>Eur Heart J</source>
<year>2007</year>
<volume>28</volume>
<issue>20</issue>
<fpage>2539</fpage>
<lpage>2550</lpage></element-citation>
<mixed-citation>15. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J.. 2007;28(20):2539-50.</mixed-citation></ref>
<ref id="B16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Nagueh</surname><given-names>SF</given-names></name>
<name><surname>Smiseth</surname><given-names>OA</given-names></name>
<name><surname>Appleton</surname><given-names>CP</given-names></name>
<name><surname>Byrd</surname><given-names>BF</given-names><suffix>3rd</suffix></name>
<name><surname>Dokainish</surname><given-names>H</given-names></name>
<name><surname>Edvardsen</surname><given-names>T</given-names></name>
<etal/></person-group>
<article-title>Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging</article-title>
<source>J Am soc Echocardiogr:</source>
<year>2016</year>
<volume>29</volume>
<issue>4</issue>
<fpage>277</fpage>
<lpage>314</lpage></element-citation>
<mixed-citation>16. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, 3rd, Dokainish H, Edvardsen T, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am soc Echocardiogr:. 2016;29(4):277-314.</mixed-citation></ref>
<ref id="B17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wassertheurer</surname><given-names>S</given-names></name>
<name><surname>Kropf</surname><given-names>J</given-names></name>
<name><surname>Weber</surname><given-names>T</given-names></name>
<name><surname>van der Giet</surname><given-names>M</given-names></name>
<name><surname>Baulmann</surname><given-names>J</given-names></name>
<name><surname>Ammer</surname><given-names>M</given-names></name>
<etal/></person-group>
<article-title>A new oscillometric method for pulse wave analysis: comparison with a common tonometric method</article-title>
<source>J Hum Hypert</source>
<year>2010</year>
<volume>24</volume>
<issue>8</issue>
<fpage>498</fpage>
<lpage>504</lpage></element-citation>
<mixed-citation>17. Wassertheurer S, Kropf J, Weber T, van der Giet M, Baulmann J, Ammer M, et al. A new oscillometric method for pulse wave analysis: comparison with a common tonometric method. J Hum Hypert. 2010;24(8):498-504.</mixed-citation></ref>
<ref id="B18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<collab>ATS/ERS</collab></person-group>
<article-title>Statement on respiratory muscle testing</article-title>
<source>Am J Respir Crit Crit Med</source>
<year>2002</year>
<volume>166</volume>
<issue>4</issue>
<fpage>518</fpage>
<lpage>624</lpage></element-citation>
<mixed-citation>18. ATS/ERS Statement on respiratory muscle testing. Am J Respir Crit Crit Med. 2002;166(4):518-624.</mixed-citation></ref>
<ref id="B19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Neder</surname><given-names>JA</given-names></name>
<name><surname>Andreoni</surname><given-names>S</given-names></name>
<name><surname>Lerario</surname><given-names>MC</given-names></name>
<name><surname>Nery</surname><given-names>LE</given-names></name></person-group>
<article-title>Reference values for lung function tests. II. Maximal respiratory pressures and voluntary ventilation</article-title>
<source>Brazilian journal of medical and biological research = Ver Bras Pesq Med Biol</source>
<year>1999</year>
<volume>32</volume>
<issue>6</issue>
<fpage>719</fpage>
<lpage>727</lpage></element-citation>
<mixed-citation>19. Neder JA, Andreoni S, Lerario MC, Nery LE. Reference values for lung function tests. II. Maximal respiratory pressures and voluntary ventilation. Brazilian journal of medical and biological research = Ver Bras Pesq Med Biol. 1999;32(6):719-27.</mixed-citation></ref>
<ref id="B20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<collab>ATS</collab></person-group>
<article-title>statement: guidelines for the six-minute walk test</article-title>
<source>Am J Respir Crit care Med</source>
<year>2002</year>
<volume>166</volume>
<issue>1</issue>
<fpage>111</fpage>
<lpage>117</lpage></element-citation>
<mixed-citation>20. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit care Med. 2002;166(1):111-7.</mixed-citation></ref>
<ref id="B21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Tsukiyama</surname><given-names>Y</given-names></name>
<name><surname>Ito</surname><given-names>T</given-names></name>
<name><surname>Nagaoka</surname><given-names>K</given-names></name>
<name><surname>Eguchi</surname><given-names>E</given-names></name>
<name><surname>Ogino</surname><given-names>K</given-names></name></person-group>
<article-title>Effects of exercise training on nitric oxide, blood pressure and antioxidant enzymes</article-title>
<source>J Clin Biochem Nutr</source>
<year>2017</year>
<volume>60</volume>
<issue>3</issue>
<fpage>180</fpage>
<lpage>186</lpage></element-citation>
<mixed-citation>21. Tsukiyama Y, Ito T, Nagaoka K, Eguchi E, Ogino K. Effects of exercise training on nitric oxide, blood pressure and antioxidant enzymes. J Clin Biochem Nutr. 2017;60(3):180-6.</mixed-citation></ref>
<ref id="B22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Vlachopoulos</surname><given-names>C</given-names></name>
<name><surname>Aznaouridis</surname><given-names>K</given-names></name>
<name><surname>Stefanadis</surname><given-names>C</given-names></name></person-group>
<article-title>Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis</article-title>
<source>J Am Coll Cardiol</source>
<year>2010</year>
<volume>55</volume>
<issue>13</issue>
<fpage>1318</fpage>
<lpage>1327</lpage></element-citation>
<mixed-citation>22. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55(13):1318-27.</mixed-citation></ref>
<ref id="B23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Celentano</surname><given-names>A</given-names></name>
<name><surname>Palmieri</surname><given-names>V</given-names></name>
<name><surname>Di Palma Esposito</surname><given-names>N</given-names></name>
<name><surname>Pietropaolo</surname><given-names>I</given-names></name>
<name><surname>Arezzi</surname><given-names>E</given-names></name>
<name><surname>Mureddu</surname><given-names>GF</given-names></name>
<etal/></person-group>
<article-title>Relations of pulse pressure and other components of blood pressure to preclinical echocardiographic abnormalities</article-title>
<source>J Hypertens</source>
<year>2002</year>
<volume>20</volume>
<issue>3</issue>
<fpage>531</fpage>
<lpage>537</lpage></element-citation>
<mixed-citation>23. Celentano A, Palmieri V, Di Palma Esposito N, Pietropaolo I, Arezzi E, Mureddu GF, et al. Relations of pulse pressure and other components of blood pressure to preclinical echocardiographic abnormalities. J Hypertens. 2002;20(3):531-7.</mixed-citation></ref>
<ref id="B24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Fang</surname><given-names>J</given-names></name>
<name><surname>Madhavan</surname><given-names>S</given-names></name>
<name><surname>Alderman</surname><given-names>MH</given-names></name></person-group>
<article-title>Pulse pressure: a predictor of cardiovascular mortality among young normotensive subjects</article-title>
<source>Blood Press</source>
<year>2000</year>
<volume>9</volume>
<issue>5</issue>
<fpage>260</fpage>
<lpage>266</lpage></element-citation>
<mixed-citation>24. Fang J, Madhavan S, Alderman MH. Pulse pressure: a predictor of cardiovascular mortality among young normotensive subjects. Blood Press. 2000;9(5):260-6.</mixed-citation></ref>
<ref id="B25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Arena</surname><given-names>R</given-names></name>
<name><surname>Cahalin</surname><given-names>LP</given-names></name></person-group>
<article-title>Evaluation of cardiorespiratory fitness and respiratory muscle function in the obese population</article-title>
<source>Progr Cardiovasc Dis</source>
<year>2014</year>
<volume>56</volume>
<issue>4</issue>
<fpage>457</fpage>
<lpage>464</lpage></element-citation>
<mixed-citation>25. Arena R, Cahalin LP. Evaluation of cardiorespiratory fitness and respiratory muscle function in the obese population. Progr Cardiovasc Dis.2014;56(4):457-64.</mixed-citation></ref>
<ref id="B26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Weiner</surname><given-names>P</given-names></name>
<name><surname>Waizman</surname><given-names>J</given-names></name>
<name><surname>Weiner</surname><given-names>M</given-names></name>
<name><surname>Rabner</surname><given-names>M</given-names></name>
<name><surname>Magadle</surname><given-names>R</given-names></name>
<name><surname>Zamir</surname><given-names>D</given-names></name></person-group>
<article-title>Influence of excessive weight loss after gastroplasty for morbid obesity on respiratory muscle performance</article-title>
<source>Thorax</source>
<year>1998</year>
<volume>53</volume>
<issue>1</issue>
<fpage>39</fpage>
<lpage>42</lpage></element-citation>
<mixed-citation>26. Weiner P, Waizman J, Weiner M, Rabner M, Magadle R, Zamir D. Influence of excessive weight loss after gastroplasty for morbid obesity on respiratory muscle performance. Thorax. 1998;53(1):39-42.</mixed-citation></ref>
<ref id="B27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Villiot-Danger</surname><given-names>JC</given-names></name>
<name><surname>Villiot-Danger</surname><given-names>E</given-names></name>
<name><surname>Borel</surname><given-names>JC</given-names></name>
<name><surname>Pepin</surname><given-names>JL</given-names></name>
<name><surname>Wuyam</surname><given-names>B</given-names></name>
<name><surname>Verges</surname><given-names>S</given-names></name></person-group>
<article-title>Respiratory muscle endurance training in obese patients</article-title>
<source>Intern J Obes</source>
<year>2005-2011</year>
<volume>35</volume>
<issue>5</issue>
<fpage>692</fpage>
<lpage>699</lpage></element-citation>
<mixed-citation>27. Villiot-Danger JC, Villiot-Danger E, Borel JC, Pepin JL, Wuyam B, Verges S. Respiratory muscle endurance training in obese patients. Intern J Obes.2005-2011;35(5):692-9.</mixed-citation></ref>
<ref id="B28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Filusch</surname><given-names>A</given-names></name>
<name><surname>Ewert</surname><given-names>R</given-names></name>
<name><surname>Altesellmeier</surname><given-names>M</given-names></name>
<name><surname>Zugck</surname><given-names>C</given-names></name>
<name><surname>Hetzer</surname><given-names>R</given-names></name>
<name><surname>Borst</surname><given-names>MM</given-names></name>
<etal/></person-group>
<article-title>Respiratory muscle dysfunction in congestive heart failure-the role of pulmonary hypertension</article-title>
<source>Internat J Cardiol</source>
<year>2011</year>
<volume>150</volume>
<issue>2</issue>
<fpage>182</fpage>
<lpage>185</lpage></element-citation>
<mixed-citation>28. Filusch A, Ewert R, Altesellmeier M, Zugck C, Hetzer R, Borst MM, et al. Respiratory muscle dysfunction in congestive heart failure-the role of pulmonary hypertension. Internat J Cardiol.2011;150(2):182-5.</mixed-citation></ref>
<ref id="B29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ponikowski</surname><given-names>P</given-names></name>
<name><surname>Francis</surname><given-names>DP</given-names></name>
<name><surname>Piepoli</surname><given-names>MF</given-names></name>
<name><surname>Davies</surname><given-names>LC</given-names></name>
<name><surname>Chua</surname><given-names>TP</given-names></name>
<name><surname>Davos</surname><given-names>CH</given-names></name>
<etal/></person-group>
<article-title>Enhanced ventilatory response to exercise in patients with chronic heart failure and preserved exercise tolerance: marker of abnormal cardiorespiratory reflex control and predictor of poor prognosis</article-title>
<source>Circulation</source>
<year>2001</year>
<volume>103</volume>
<issue>7</issue>
<fpage>967</fpage>
<lpage>972</lpage></element-citation>
<mixed-citation>29. Ponikowski P, Francis DP, Piepoli MF, Davies LC, Chua TP, Davos CH, et al. Enhanced ventilatory response to exercise in patients with chronic heart failure and preserved exercise tolerance: marker of abnormal cardiorespiratory reflex control and predictor of poor prognosis. Circulation. 2001;103(7):967-72.</mixed-citation></ref>
<ref id="B30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Derchak</surname><given-names>PA</given-names></name>
<name><surname>Sheel</surname><given-names>AW</given-names></name>
<name><surname>Morgan</surname><given-names>BJ</given-names></name>
<name><surname>Dempsey</surname><given-names>JA</given-names></name></person-group>
<article-title>Effects of expiratory muscle work on muscle sympathetic nerve activity</article-title>
<source>J Appl Physiol</source>
<year>2002</year>
<volume>92</volume>
<issue>4</issue>
<fpage>1539</fpage>
<lpage>1552</lpage></element-citation>
<mixed-citation>30. Derchak PA, Sheel AW, Morgan BJ, Dempsey JA. Effects of expiratory muscle work on muscle sympathetic nerve activity. J Appl Physiol.. 2002;92(4):1539-52.</mixed-citation></ref>
<ref id="B31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Harms</surname><given-names>CA</given-names></name>
<name><surname>Wetter</surname><given-names>TJ</given-names></name>
<name><surname>McClaran</surname><given-names>SR</given-names></name>
<name><surname>Pegelow</surname><given-names>DF</given-names></name>
<name><surname>Nickele</surname><given-names>GA</given-names></name>
<name><surname>Nelson</surname><given-names>WB</given-names></name>
<etal/></person-group>
<article-title>Effects of respiratory muscle work on cardiac output and its distribution during maximal exercise</article-title>
<source>J Appl Physiol</source>
<year>1998</year>
<volume>85</volume>
<issue>2</issue>
<fpage>609</fpage>
<lpage>618</lpage></element-citation>
<mixed-citation>31. Harms CA, Wetter TJ, McClaran SR, Pegelow DF, Nickele GA, Nelson WB, et al. Effects of respiratory muscle work on cardiac output and its distribution during maximal exercise. J Appl Physiol 1998;85(2):609-18.</mixed-citation></ref>
<ref id="B32">
<label>32</label>
<element-citation publication-type="journal">
<article-title>Yoga and breathing technique training in patients with heart failure and preserved ejection fraction: study protocol for a randomized clinical trial</article-title>
<person-group person-group-type="editor">
<name><surname>Lopes</surname><given-names>CP</given-names></name>
<name><surname>Danzmann</surname><given-names>LC</given-names></name>
<name><surname>Moraes</surname><given-names>RS</given-names></name>
<name><surname>Vieira</surname><given-names>PJC</given-names></name>
<name><surname>Meurer</surname><given-names>FF</given-names></name>
<name><surname>Soares</surname><given-names>DS</given-names></name>
<name><surname>Chiappa</surname><given-names>G</given-names></name>
<name><surname>Guimar&#xE2;es</surname><given-names>LSP</given-names></name>
<name><surname>Leit&#xE3;o</surname><given-names>SAT</given-names></name>
<name><surname>Ribeiro</surname><given-names>JP</given-names></name></person-group>
<source>Biolo A. Trials</source>
<year>2018</year>
<volume>19</volume>
<issue>1</issue>
<fpage>405</fpage>
<lpage>405</lpage></element-citation>
<mixed-citation>32. Yoga and breathing technique training in patients with heart failure and preserved ejection fraction: study protocol for a randomized clinical trial. Lopes CP, Danzmann LC, Moraes RS, Vieira PJC, Meurer FF, Soares DS, Chiappa G, Guimar&#xE2;es LSP, Leit&#xE3;o SAT, Ribeiro JP, Biolo A. Trials. 2018;19(1):405.</mixed-citation></ref>
<ref id="B33">
<label>33</label>
<element-citation publication-type="other">
<article-title>Training and Functional Electrical Stimulation for Treatment of Heart Failure With Preserved Ejection Fraction: The TRAINING-HF Trial</article-title>
<source>Rev Esp Cardiol</source>
<year>2019</year>
<volume>72</volume>
<issue>4</issue>
<fpage>288</fpage>
<lpage>297</lpage></element-citation>
<mixed-citation>33. Training and Functional Electrical Stimulation for Treatment of Heart Failure With Preserved Ejection Fraction: The TRAINING-HF Trial. Rev Esp Cardiol 2019;72(4):288-97.</mixed-citation></ref></ref-list>
</back>
<sub-article article-type="translation" id="S01" xml:lang="pt">
<front-stub>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Artigo Original</subject></subj-group></article-categories>
<title-group>
<article-title>Treinamento Muscular Inspirat&#xF3;rio Agudo Modifica os &#xCD;ndices Hemodin&#xE2;micos em Pacientes com Insufici&#xEA;ncia Card&#xED;aca com Fra&#xE7;&#xE3;o de Eje&#xE7;&#xE3;o Preservada</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">0000-0001-8158-6151</contrib-id>
<name><surname>Menezes</surname><given-names>M&#xE1;rcio Garcia</given-names></name><xref ref-type="aff" rid="aff5"><sup>1</sup></xref></contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">0000-0002-8126-7211</contrib-id>
<name><surname>Garcia</surname><given-names>Eduardo Lima</given-names></name><xref ref-type="aff" rid="aff5"><sup>1</sup></xref> <xref ref-type="aff" rid="aff7"><sup>3</sup></xref></contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">0000-0002-6327-1428</contrib-id>
<name><surname>Franzoni</surname><given-names>Leandro Tolfo</given-names></name><xref ref-type="aff" rid="aff5"><sup>1</sup></xref> <xref ref-type="aff" rid="aff7"><sup>3</sup></xref> <xref ref-type="aff" rid="aff8"><sup>4</sup></xref></contrib>
<contrib contrib-type="author">
<name><surname>Grings</surname><given-names>Vanessa</given-names></name><xref ref-type="aff" rid="aff5"><sup>1</sup></xref></contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">0000-0002-5774-2780</contrib-id>
<name><surname>Danzmann</surname><given-names>Luiz Claudio</given-names></name><xref ref-type="aff" rid="aff5"><sup>1</sup></xref> <xref ref-type="aff" rid="aff6"><sup>2</sup></xref> <xref ref-type="corresp" rid="c2"/></contrib>
<aff id="aff5">
<label>1</label>
<addr-line>
<named-content content-type="city">Canoas</named-content>
<named-content content-type="state">RS</named-content></addr-line>
<country country="BR">Brasil</country>
<institution content-type="original">Departamento de Cardiologia, Faculdade de Medicina da Universidade Luterana do Brasil, Canoas, RS - Brasil</institution></aff>
<aff id="aff6">
<label>2</label>
<addr-line>
<named-content content-type="city">Porto Alegre</named-content>
<named-content content-type="state">RS</named-content></addr-line>
<country country="BR">Brasil</country>
<institution content-type="original">Hospital S&#xE3;o Lucas da Pontif&#xED;cia Universidade Cat&#xF3;lica do Rio Grande do Sul PUCRS, Porto Alegre, RS - Brasil</institution></aff>
<aff id="aff7">
<label>3</label>
<addr-line>
<named-content content-type="city">Porto Alegre</named-content>
<named-content content-type="state">RS</named-content></addr-line>
<country country="BR">Brasil</country>
<institution content-type="original">Setor de Reabilita&#xE7;&#xE3;o Card&#xED;aca, Hospital de Cl&#xED;nicas de Porto Alegre, Porto Alegre, RS - Brasil</institution></aff>
<aff id="aff8">
<label>4</label>
<addr-line>
<named-content content-type="city">Porto Alegre</named-content>
<named-content content-type="state">RS</named-content></addr-line>
<country country="BR">Brasil</country>
<institution content-type="original">Programa de P&#xF3;s-Gradua&#xE7;&#xE3;o em Ci&#xEA;ncias da Sa&#xFA;de: Cardiologia e Ci&#xEA;ncias Cardiovasculares da Universidade Federal do Rio Grande do Sul, Porto Alegre, RS - Brasil</institution></aff></contrib-group>
<author-notes>
<corresp id="c2"><bold>Correspond&#xEA;ncia: Luiz Claudio Danzmann</bold> &#x2022; Rua Visconde do Herval, 472/903. CEP <postal-code>90130-150</postal-code>, Porto Alegre, RS - Brasil. E-mail <email>luiz.danzmann@ulbra.br</email></corresp>
<fn fn-type="con">
<p><bold>Contribui&#xE7;&#xE3;o dos autores</bold></p>
<p>Concep&#xE7;&#xE3;o e desenho da pesquisa e Obten&#xE7;&#xE3;o de dados: Menezes MG, Garcia EL, Grings V, Danzmann LC; An&#xE1;lise e interpreta&#xE7;&#xE3;o dos dados: Menezes MG, Grings V, Danzmann LC; An&#xE1;lise estat&#xED;stica: Menezes MG, Franzoni LT, Danzmann LC; Obten&#xE7;&#xE3;o de financiamento: Menezes MG, Danzmann LC; Reda&#xE7;&#xE3;o do manuscrito e Revis&#xE3;o cr&#xED;tica do manuscrito quanto ao conte&#xFA;do intelectual importante: Menezes MG, Garcia EL, Franzoni LT, Grings V, Danzmann LC.</p></fn>
<fn fn-type="conflict">
<p><bold>Potencial conflito de interesse</bold></p>
<p>N&#xE3;o h&#xE1; conflito com o presente artigo</p></fn></author-notes>
<abstract>
<title>Resumo</title>
<sec>
<title>Fundamento:</title>
<p>A insufici&#xEA;ncia card&#xED;aca com fra&#xE7;&#xE3;o de eje&#xE7;&#xE3;o preservada (ICFEp), uma s&#xED;ndrome associada a diminui&#xE7;&#xE3;o da capacidade funcional, &#xE9; dif&#xED;cil de manejar. O treinamento muscular inspirat&#xF3;rio (TMI) tem sido utilizado para tratar sintomas e para melhorar a capacidade funcional de pacientes com ICFEp. Portanto, objetivamos avaliar os efeitos imediatos e 1 h ap&#xF3;s TMI na hemodin&#xE2;mica arterial puls&#xE1;til e nos &#xED;ndices hemodin&#xE2;micos de enchimento do ventr&#xED;culo esquerdo derivados de ecocardiograma Doppler em pacientes com ICFEp.</p>
</sec>
<sec>
<title>M&#xE9;todos:</title>
<p>Dezoito pacientes com ICFEp submetidos a TMI a uma intensidade de 80% da press&#xE3;o inspirat&#xF3;ria m&#xE1;xima foram avaliados por ecocardiograma Doppler nos per&#xED;odos pr&#xE9;, p&#xF3;s-imediato e p&#xF3;s-tardio; al&#xE9;m disso, foram coletadas vari&#xE1;veis hemodin&#xE2;micas puls&#xE1;teis. A capacidade funcional foi avaliada utilizando o teste de caminhada de 6 minutos.</p>
</sec>
<sec>
<title>Resultados:</title>
<p>A popula&#xE7;&#xE3;o foi composta predominantemente de mulheres (66,7%), m&#xE9;dia de idade de 61,3 (DP,7,2) anos. Foram observadas modifica&#xE7;&#xF5;es no &#xED;ndice n&#xE3;o invasivo de press&#xE3;o de enchimento do VE (E/e&#x2019;) (pr&#xE9;: 10,33 (DP, 3,15) vs p&#xF3;s: 8,73 (DP, 2,24); p &#x3C; 0,001) e na velocidade de onda de pulso (pr&#xE9;: 8,33 (DP, 1,67) vs p&#xF3;s: 7,63 (DP, 1,66) m/s; p &#x3C; 0,001), assim como na press&#xE3;o de pulso (pr&#xE9;: 54,81 (DP, 18,73) vs p&#xF3;s: 48,52 (DP, 15,74) mm Hg; p = 0,023).</p>
</sec>
<sec>
<title>Conclus&#xE3;o:</title>
<p>Nossos resultados demonstraram que uma &#xFA;nica sess&#xE3;o de TMI de alta intensidade melhora os &#xED;ndices hemodin&#xE2;micos de enchimento do VE e rigidez arterial em pacientes com ICFEp.</p>
</sec></abstract>
<kwd-group xml:lang="pt">
<title>Palavras-chave:</title>
<kwd>Insufici&#xEA;ncia Card&#xED;aca/fisiopatologia</kwd>
<kwd>Volume Sist&#xF3;lico</kwd>
<kwd>Volume de Reserva Respirat&#xF3;rio</kwd>
<kwd>Hemodin&#xE2;mica</kwd>
<kwd>Ecocardiografia/m&#xE9;todos</kwd>
<kwd>Reabilita&#xE7;&#xE3;o</kwd>
<kwd>Pneumologia</kwd>
<kwd>Sistema Respirat&#xF3;rio</kwd>
<kwd>Dispneia</kwd></kwd-group></front-stub>
<body>
<sec sec-type="intro">
<title>Introdu&#xE7;&#xE3;o</title>
<p>A insufici&#xEA;ncia card&#xED;aca com fra&#xE7;&#xE3;o de eje&#xE7;&#xE3;o preservada (ICFEp) &#xE9; uma s&#xED;ndrome cl&#xED;nica com maior preval&#xEA;ncia em mulheres, idosos, hipertensos e diab&#xE9;ticos.<xref ref-type="bibr" rid="B1"><sup>1</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B2"><sup>2</sup></xref> Seu principal mecanismo de a&#xE7;&#xE3;o &#xE9; a disfun&#xE7;&#xE3;o fisiopatol&#xF3;gica do enchimento do ventr&#xED;culo esquerdo (VE). Tal disfun&#xE7;&#xE3;o pode resultar em aumento da press&#xE3;o de enchimento do VE, da press&#xE3;o atrial esquerda e da press&#xE3;o arterial pulmonar, as quais podem estar alteradas no momento basal ou durante exerc&#xED;cio.<xref ref-type="bibr" rid="B3"><sup>3</sup></xref> Dispneia e fadiga s&#xE3;o sintomas comuns em pacientes com ICFEp, sendo uma das principais causas de intoler&#xE2;ncia ao exerc&#xED;cio.<xref ref-type="bibr" rid="B4"><sup>4</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B5"><sup>5</sup></xref></p>
<p>Rigidez arterial, tanto central quanto perif&#xE9;rica, representa outro mecanismo importante para o desenvolvimento da ICFEp. Altera&#xE7;&#xF5;es nos &#xED;ndices hemodin&#xE2;micos puls&#xE1;teis est&#xE3;o associadas a intoler&#xE2;ncia ao esfor&#xE7;o, pois indicam piora do acoplamento ventr&#xED;culo-arterial, basicamente devido ao aumento excessivo da p&#xF3;s-carga do VE, prejudicando o desempenho da eje&#xE7;&#xE3;o do VE.<xref ref-type="bibr" rid="B6"><sup>6</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B8"><sup>8</sup></xref></p>
<p>Al&#xE9;m dos fatores cardiovasculares, a for&#xE7;a muscular respirat&#xF3;ria (FMR) tem papel adicional no desempenho hemodin&#xE2;mico global, influenciando o d&#xE9;bito card&#xED;aco, a press&#xE3;o pulmonar e a resist&#xEA;ncia arterial pulmonar, o que contribui para a ativa&#xE7;&#xE3;o dos reflexos cardiovasculares, limitando a toler&#xE2;ncia ao exerc&#xED;cio em pacientes com ICFEp.<bold>9-12</bold></p>
<p>O treinamento muscular inspirat&#xF3;rio (TMI) em intensidade moderada [30% da press&#xE3;o inspirat&#xF3;ria m&#xE1;xima (PIM)] j&#xE1; tem apresentado benef&#xED;cios na capacidade funcional e na qualidade de vida de pacientes com ICFEp.<xref ref-type="bibr" rid="B13"><sup>13</sup></xref> Entretanto, dados sobre os efeitos do TMI na fun&#xE7;&#xE3;o de enchimento do VE e no comportamento da hemodin&#xE2;mica arterial puls&#xE1;til n&#xE3;o foram devidamente investigados, especialmente em intensidades superiores a 30% da PIM. Portanto, este estudo tem o objetivo de avaliar o efeito imediato e 1 h ap&#xF3;s o TMI a 80% da PIM na fun&#xE7;&#xE3;o diast&#xF3;lica do VE e na rigidez arterial em pacientes com ICFEp.</p>
</sec>
<sec sec-type="methods">
<title>M&#xE9;todos</title>
<sec>
<title>Desenho e popula&#xE7;&#xE3;o do estudo</title>
<p>Trata-se de um estudo transversal quase-experimental. Foram inclu&#xED;dos pacientes de um hospital terci&#xE1;rio do sul do Brasil com idade acima de 45 anos que atendiam aos crit&#xE9;rios da Sociedade Europeia de Cardiologia (<italic>European Society of Cardiology</italic>) para ICFEp no momento em que o estudo foi elaborado<xref ref-type="bibr" rid="B14"><sup>14</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B15"><sup>15</sup></xref> e que estavam clinicamente est&#xE1;veis sem hospitaliza&#xE7;&#xE3;o pr&#xE9;via de 30 dias. Foram exclu&#xED;dos pacientes com angina <italic>pectoris</italic>, fibrila&#xE7;&#xE3;o atrial ou flutter atrial durante o exame, pericardiopatias e problemas musculoesquel&#xE9;ticos que impedissem a realiza&#xE7;&#xE3;o do teste de capacidade funcional.</p>
<p>Ap&#xF3;s convite inicial, os pacientes foram informados sobre o ecocardiograma para avaliar os &#xED;ndices card&#xED;acos e confirmar o diagn&#xF3;stico; sobre avalia&#xE7;&#xE3;o da FMR pela PIM e pela press&#xE3;o expirat&#xF3;ria m&#xE1;xima (PEM); sobre o teste de caminhada de 6 minutos (TC6M); e sobre a avalia&#xE7;&#xE3;o da hemodin&#xE2;mica arterial puls&#xE1;til. Os pacientes que concordaram em participar do presente estudo assinaram um formul&#xE1;rio de consentimento livre e esclarecido, de acordo com o projeto aprovado pelo comit&#xEA; de &#xE9;tica da respectiva institui&#xE7;&#xE3;o (39338614.0000.53.49).</p>
</sec>
</sec>
<sec>
<title>Avalia&#xE7;&#xE3;o das vari&#xE1;veis</title>
<sec>
<title>Ecocardiograma</title>
<p>A avalia&#xE7;&#xE3;o da hemodin&#xE2;mica do VE foi realizada por ecocardiograma Doppler dimensional utilizando o modo M-10 padr&#xE3;o (Siemens Acuson X 300, Siemens Medical Solutions USA Malvern, EUA), seguindo as recomenda&#xE7;&#xF5;es da Sociedade Americana de Ecocardiografia (<italic>American Society of Echocardiography</italic>).<xref ref-type="bibr" rid="B16"><sup>16</sup></xref> Os ecocardiogramas foram realizados pelo mesmo operador. Todos os registros ecocardiogr&#xE1;ficos foram obtidos em formato digital e registrados com uma m&#xE9;dia de 3 ciclos card&#xED;acos para an&#xE1;lise. Os registros do Doppler espectral do fluxo mitral foram obtidos a partir da visualiza&#xE7;&#xE3;o das 4 c&#xE2;maras para avaliar a din&#xE2;mica do enchimento do VE. Foram mensuradas as seguintes vari&#xE1;veis: velocidades de transmiss&#xE3;o durante os picos inicial (onda E) e tardio (onda A) do enchimento em cent&#xED;metros por segundo; raz&#xE3;o E/A; tempo de desacelera&#xE7;&#xE3;o da onda E em milissegundos (do pico da velocidade de E ao momento basal). Foi realizado Doppler tecidual espectral com visualiza&#xE7;&#xE3;o apical das 4 c&#xE2;maras, o volume da amostra foi definido em 5 x 5 mm e posicionado na jun&#xE7;&#xE3;o das paredes septal e lateral do VE com o anel mitral e 3 ciclos card&#xED;acos consecutivos, o que foi transferido para uma esta&#xE7;&#xE3;o de trabalho e analisado. Os picos de velocidade durante a s&#xED;stole, o in&#xED;cio da di&#xE1;stole (E&#x2019;) e o fim da di&#xE1;stole (a&#x2019;) foram mensurados e a m&#xE9;dia de ambos os locais foi analisada. O &#xED;ndice n&#xE3;o invasivo de press&#xE3;o de enchimento de VE foi avaliado pela raz&#xE3;o entre a velocidade do fluxo transmitral no in&#xED;cio da di&#xE1;stole e a velocidade de movimenta&#xE7;&#xE3;o do tecido anular mitral (E/e&#x2019;). O exame foi realizado antes da avalia&#xE7;&#xE3;o da FMR, imediatamente ap&#xF3;s o TMI (p&#xF3;s-imediato), e 1 hora ap&#xF3;s TMI (p&#xF3;s-tardio).</p>
</sec>
<sec>
<title>Rigidez arterial mensurada por velocidade de onda de pulso</title>
<p>A avalia&#xE7;&#xE3;o da rigidez arterial foi realizada atrav&#xE9;s da an&#xE1;lise da velocidade de onda de pulso (VOP) e press&#xE3;o de pulso (PP) baseada no m&#xE9;todo oscilom&#xE9;trico, utilizando os dados da press&#xE3;o da art&#xE9;ria braquial. Os registros foram realizados em n&#xED;vel de press&#xE3;o diast&#xF3;lica por aproximadamente 10 s utilizando um manguito adulto convencional para medi&#xE7;&#xE3;o da press&#xE3;o arterial, dispon&#xED;vel em 2 tamanhos (24-34 e 32-42 cm), e um sensor de press&#xE3;o de alta precis&#xE3;o (Mobil-O-Graph NG, IEM GmbH, Stolberg, Alemanha).<xref ref-type="bibr" rid="B17"><sup>17</sup></xref></p>
</sec>
<sec>
<title>Teste de for&#xE7;a muscular respirat&#xF3;ria</title>
<p>A FMR sempre foi avaliada pelo mesmo examinador atrav&#xE9;s da mensura&#xE7;&#xE3;o da PIM e da PEM. As medi&#xE7;&#xF5;es foram obtidas utilizando um monitor de press&#xE3;o (Globalmed MVD300, Porto Alegre, Brasil). Os procedimentos foram repetidos 6 vezes, e as 3 maiores medidas foram consideradas v&#xE1;lidas, desde que a varia&#xE7;&#xE3;o entre elas n&#xE3;o fosse superior a 10%, de acordo com a diretriz para testes de fun&#xE7;&#xE3;o pulmonar.<xref ref-type="bibr" rid="B18"><sup>18</sup></xref> Os pacientes permaneceram sentados, com os ombros apoiados, e foi utilizado um clipe nasal. O ar passava atrav&#xE9;s do bocal transmitia o n&#xED;vel de press&#xE3;o para o transdutor de press&#xE3;o. A PIM e a PEM foram definidas como os valores mais elevados das 3 medidas selecionadas.<xref ref-type="bibr" rid="B19"><sup>19</sup></xref> A intensidade do TMI foi determinada pela maior PIM (80%) para o protocolo de treinamento. O teste foi realizado ap&#xF3;s o ecocardiograma e a avalia&#xE7;&#xE3;o da hemodin&#xE2;mica puls&#xE1;til.</p>
</sec>
<sec>
<title>Teste de caminhada de 6 minutos</title>
<p>O TC6M sempre foi realizado pelo mesmo avaliador, de acordo com as recomenda&#xE7;&#xF5;es da Sociedade Tor&#xE1;cica Americana (<italic>American Thoracic Society</italic>).<xref ref-type="bibr" rid="B20"><sup>20</sup></xref> O teste foi realizado em um corredor adaptado com marca&#xE7;&#xF5;es a cada 30 metros. Os pacientes foram orientados a caminhar a maior dist&#xE2;ncia poss&#xED;vel em 6 minutos, sempre com encorajamento. Foram verificadas as press&#xF5;es arteriais pr&#xE9; e p&#xF3;s-esfor&#xE7;o, e a frequ&#xEA;ncia card&#xED;aca foi monitorada durante o teste.</p>
</sec>
</sec>
<sec>
<title>Protocolo de interven&#xE7;&#xE3;o</title>
<sec>
<title>Treinamento muscular inspirat&#xF3;rio</title>
<p>Os indiv&#xED;duos foram submetidos a 1 sess&#xE3;o de TMI com intensidade de 80% da PIM. Foi utilizado o modelo PowerBreathe Classic <italic>light resistance</italic>, com a intensidade ajustada de 10 a 90 cm H<sub>2</sub>O. Foram realizadas 3 s&#xE9;ries de 10 minutos, com um intervalo de 1 minuto entre cada s&#xE9;rie. Ap&#xF3;s a conclus&#xE3;o do TMI, os pacientes foram submetidos novamente a avalia&#xE7;&#xE3;o ecocardiogr&#xE1;fica e da din&#xE2;mica puls&#xE1;til para avaliar os efeitos imediatos. Al&#xE9;m disso, esperaram 1 hora em descanso para repetir as avalia&#xE7;&#xF5;es.</p>
</sec>
</sec>
<sec>
<title>An&#xE1;lise estat&#xED;stica</title>
<p>As vari&#xE1;veis foram descritas em frequ&#xEA;ncia simples e relativa para vari&#xE1;veis categ&#xF3;ricas, e m&#xE9;dia e desvio padr&#xE3;o para vari&#xE1;veis cont&#xED;nuas. Para analisar as diferen&#xE7;as entre vari&#xE1;veis cont&#xED;nuas e categ&#xF3;ricas nos per&#xED;odos pr&#xE9;, p&#xF3;s-imediato e p&#xF3;s-tardio, foram utilizados o m&#xE9;todo de equa&#xE7;&#xF5;es de estima&#xE7;&#xE3;o generalizadas e a correla&#xE7;&#xE3;o de Bonferroni para m&#xFA;ltiplas compara&#xE7;&#xF5;es. Para o c&#xE1;lculo do tamanho da amostra, esperando-se obter uma diferen&#xE7;a de 3,3 na raz&#xE3;o E/e&#x2019; antes e depois do protocolo e considerando um poder de 80% e um erro alfa de 5%, estimamos uma amostra de 18 participantes. Os dados foram analisados utilizando o programa estat&#xED;stico SPSS, vers&#xE3;o 18.0.</p>
</sec>
<sec sec-type="results">
<title>Resultados</title>
<p>A popula&#xE7;&#xE3;o do estudo consistiu em 18 indiv&#xED;duos, com predomin&#xE2;ncia do g&#xEA;nero feminino. As principais comorbidades associadas foram hipertens&#xE3;o arterial sist&#xEA;mica, diabetes melito e obesidade; al&#xE9;m disso, a terapia medicamentosa mais utilizada foi betabloqueadores.</p>
<p>Embora a amostra tenha apresentado valores caracter&#xED;sticos de disfun&#xE7;&#xE3;o diast&#xF3;lica moderada (E/e&#x2019;), a dist&#xE2;ncia percorrida no TC6M demonstrou boa capacidade funcional, representando a m&#xE9;dia absoluta para indiv&#xED;duos classificados na classe A de Weber. Ademais, os valores de VOP pareciam estar dentro da normalidade para rigidez arterial, assim como para d&#xE9;bito card&#xED;aco (3,94 (0,17) L/min) e &#xED;ndice card&#xED;aco (2,05 (0,09) L/min/m<sup>2</sup>). Entretanto, os valores de PP estavam elevando, identificando poss&#xED;vel rigidez a&#xF3;rtica com regurgita&#xE7;&#xE3;o valvar. As caracter&#xED;sticas basais da amostra est&#xE3;o descritas na <xref ref-type="table" rid="t2">Tabela 1</xref>.</p>
<table-wrap id="t2">
<label>Tabela 1</label>
<caption>
<title>Caracter&#xED;sticas antropom&#xE9;tricas, respirat&#xF3;rias, ecocardiogr&#xE1;ficas e hemodin&#xE2;micas</title></caption>
<table frame="hsides" rules="rows">
<colgroup width="50%">
<col/>
<col/></colgroup>
<thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000">
<tr>
<th align="left" valign="middle">Vari&#xE1;veis (N = 18)</th>
<th align="center" valign="middle">Valores (m&#xE9;dia (DP) ou %)</th></tr></thead>
<tbody style="border-bottom: thin solid; border-color: #000000">
<tr>
<td align="left" valign="middle"><bold>Dados antropom&#xE9;tricos</bold></td>
<td align="center" valign="middle"/></tr>
<tr>
<td align="left" valign="middle">Idade (anos)</td>
<td align="center" valign="middle">61,3 (7,2)</td></tr>
<tr>
<td align="left" valign="middle">Altura (cm)</td>
<td align="center" valign="middle">160 (0,9)</td></tr>
<tr>
<td align="left" valign="middle">Massa corporal (kg)</td>
<td align="center" valign="middle">84,1 (16,4)</td></tr>
<tr>
<td align="left" valign="middle">IMC (kg/m<sup>2</sup>)</td>
<td align="center" valign="middle">32 (4,6)</td></tr>
<tr>
<td align="left" valign="middle">Sexo feminino (%)</td>
<td align="center" valign="middle">66,7</td></tr>
<tr>
<td align="left" valign="middle"><bold>Terapia medicamentosa (%)</bold></td>
<td align="center" valign="middle"/></tr>
<tr>
<td align="left" valign="middle">Betabloqueador</td>
<td align="center" valign="middle">76,5</td></tr>
<tr>
<td align="left" valign="middle">IECA</td>
<td align="center" valign="middle">47,1</td></tr>
<tr>
<td align="left" valign="middle">BRA</td>
<td align="center" valign="middle">35,3</td></tr>
<tr>
<td align="left" valign="middle">BCC</td>
<td align="center" valign="middle">41,2</td></tr>
<tr>
<td align="left" valign="middle">Furosemida</td>
<td align="center" valign="middle">41,2</td></tr>
<tr>
<td align="left" valign="middle">Tiazida</td>
<td align="center" valign="middle">52,9</td></tr>
<tr>
<td align="left" valign="middle">ARA</td>
<td align="center" valign="middle">29,4</td></tr>
<tr>
<td align="left" valign="middle">Nitrato</td>
<td align="center" valign="middle">23,5</td></tr>
<tr>
<td align="left" valign="middle">Hidralazina</td>
<td align="center" valign="middle">11,8</td></tr>
<tr>
<td align="left" valign="middle">Antiplaquet&#xE1;rio</td>
<td align="center" valign="middle">52,9</td></tr>
<tr>
<td align="left" valign="middle"><bold>Comorbidades (%)</bold></td>
<td align="center" valign="middle"/></tr>
<tr>
<td align="left" valign="middle">Hipertens&#xE3;o arterial sist&#xEA;mica</td>
<td align="center" valign="middle">94,1</td></tr>
<tr>
<td align="left" valign="middle">Diabetes</td>
<td align="center" valign="middle">41,2</td></tr>
<tr>
<td align="left" valign="middle">Obesidade</td>
<td align="center" valign="middle">47,1</td></tr>
<tr>
<td align="left" valign="middle">Tabagismo</td>
<td align="center" valign="middle">5,9</td></tr>
<tr>
<td align="left" valign="middle">Doen&#xE7;a arterial coronariana</td>
<td align="center" valign="middle">35,3</td></tr>
<tr>
<td align="left" valign="middle">Doen&#xE7;a pulmonar obstrutiva cr&#xF4;nica</td>
<td align="center" valign="middle">5,9</td></tr>
<tr>
<td align="left" valign="middle">Insufici&#xEA;ncia renal</td>
<td align="center" valign="middle">7,3</td></tr>
<tr>
<td align="left" valign="middle">Acidente vascular cerebral</td>
<td align="center" valign="middle">4,7</td></tr>
<tr>
<td align="left" valign="middle">Doen&#xE7;a reum&#xE1;tica</td>
<td align="center" valign="middle">6,8</td></tr>
<tr>
<td align="left" valign="middle"><bold>Capacidade funcional</bold></td>
<td align="center" valign="middle"/></tr>
<tr>
<td align="left" valign="middle">NYHA I &#x2013; II (%)</td>
<td align="center" valign="middle">94,4</td></tr>
<tr>
<td align="left" valign="middle">NYHA III (%)</td>
<td align="center" valign="middle">5,6</td></tr>
<tr>
<td align="left" valign="middle">TC6M (metros)</td>
<td align="center" valign="middle">431,4 (117,2)</td></tr>
<tr>
<td align="left" valign="middle"><bold>Vari&#xE1;veis respirat&#xF3;rias</bold></td>
<td align="center" valign="middle"/></tr>
<tr>
<td align="left" valign="middle">PIM (cm H<sub>2</sub>O)</td>
<td align="center" valign="middle">73,6 (17,8)</td></tr>
<tr>
<td align="left" valign="middle">PIM prevista (cm H<sub>2</sub>O)</td>
<td align="center" valign="middle">115,8 (6,9)</td></tr>
<tr>
<td align="left" valign="middle">70% da PIM prevista (cm H<sub>2</sub>O)</td>
<td align="center" valign="middle">80,8 (4,9)</td></tr>
<tr>
<td align="left" valign="middle">PEM (cm H<sub>2</sub>O)</td>
<td align="center" valign="middle">124 (28,9)</td></tr>
<tr>
<td align="left" valign="middle">PEM prevista (cm H<sub>2</sub>O)</td>
<td align="center" valign="middle">90,8 (19)</td></tr>
<tr>
<td align="left" valign="middle">70% da PEM prevista (cm H<sub>2</sub>O)</td>
<td align="center" valign="middle">65,6 (14,8)</td></tr>
<tr>
<td align="left" valign="middle">Fraqueza inspirat&#xF3;ria (%)</td>
<td align="center" valign="middle">61,1</td></tr>
<tr>
<td align="left" valign="middle"><bold>Vari&#xE1;veis ecocardiogr&#xE1;ficas</bold></td>
<td align="center" valign="middle"/></tr>
<tr>
<td align="left" valign="middle">FE Simpson (%)</td>
<td align="center" valign="middle">64,2 (11,7)</td></tr>
<tr>
<td align="left" valign="middle">E/e&#x27;</td>
<td align="center" valign="middle">9,8 (3,6)</td></tr>
<tr>
<td align="left" valign="middle">E/A</td>
<td align="center" valign="middle">1 (0,7)</td></tr>
<tr>
<td align="left" valign="middle">TRI</td>
<td align="center" valign="middle">103,8 (87)</td></tr>
<tr>
<td align="left" valign="middle">VAE</td>
<td align="center" valign="middle">73,7 (25,7)</td></tr>
<tr>
<td align="left" valign="middle">VAEi</td>
<td align="center" valign="middle">39,4 (10,2)</td></tr>
<tr>
<td align="left" valign="middle">MVEi Teicholz (g/m&#xB2;)</td>
<td align="center" valign="middle">119,4 (47,3)</td></tr>
<tr>
<td align="left" valign="middle"><bold>Vari&#xE1;veis da hemodin&#xE2;mica puls&#xE1;til</bold></td>
<td align="center" valign="middle"/></tr>
<tr>
<td align="left" valign="middle">VOP (m/s)</td>
<td align="center" valign="middle">8,3 (1,7)</td></tr>
<tr>
<td align="left" valign="middle">PPC</td>
<td align="center" valign="middle">54,8 (4,3)</td></tr>
<tr>
<td align="left" valign="middle">Aix</td>
<td align="center" valign="middle">32,2 (12,8)</td></tr></tbody></table>
<table-wrap-foot>
<fn id="TFN2">
<p><italic>IMC: &#xED;ndice de massa corporal; IECA: inibidor da enzima conversora de angiotensina; BRA: bloqueador do receptor de angiotensina; BCC: bloqueador do canal c&#xE1;lcio; ARA: antagonista do receptor de angiotensina; NYHA; New York Heart Association; TC6M: teste de caminhada de 6 minutos; PIM: press&#xE3;o inspirat&#xF3;ria m&#xE1;xima; PEM: press&#xE3;o expirat&#xF3;ria m&#xE1;xima; FE: fra&#xE7;&#xE3;o de eje&#xE7;&#xE3;o; TRI: tempo de relaxamento isovolum&#xE9;trico; E: pico de velocidade da onda E; e&#x2019;: pico de velocidade no in&#xED;cio da di&#xE1;stole na Doppler tecidual; VAE: volume do &#xE1;trio esquerdo; VAEi: volume do &#xE1;trio esquerdo indexado; MVEi: massa do ventr&#xED;culo esquerdo indexada; VOP: velocidade da onda de pulso; PPC: press&#xE3;o de pulso central; Aix: &#xED;ndice de incremento (augmentation index).</italic></p></fn></table-wrap-foot></table-wrap>
<p>Ap&#xF3;s 1 h de TMI, observou-se uma mudan&#xE7;a significativa na raz&#xE3;o E/e&#x2019; em compara&#xE7;&#xE3;o aos valores iniciais (10,33 (DP, 3,15) vs 8,73 (DP, 2,24); p &#x3C; 0,001), al&#xE9;m de uma redu&#xE7;&#xE3;o entre os per&#xED;odos p&#xF3;s-imediato e p&#xF3;s-tardio (10,38 (DP, 3,23) m/s vs 8,73 (DP, 2,24) m/s; p &#x3C; 0,011) (<xref ref-type="fig" rid="f4">Figura 1</xref>).</p>
<fig id="f4">
<label>Figura 1</label>
<caption>
<title>Estimativa da press&#xE3;o de enchimento do ventr&#xED;culo esquerdo nos per&#xED;odos pr&#xE9;, p&#xF3;s-imediato e p&#xF3;s-tardio. * p &#x3C; 0,05 entre pr&#xE9; e p&#xF3;s-imediato; # p &#x3C; 0,05 entre p&#xF3;s-imediato e p&#xF3;s-tardio. E/e&#x2019;: &#xED;ndice n&#xE3;o invasivo de enchimento do VE.</title></caption>
<graphic xlink:href="0000-0000-abchf-001-01-0027-gf01-pt.tif"/></fig>
<p>Com rela&#xE7;&#xE3;o &#xE0; rigidez arterial, houve mudan&#xE7;as significativas na VOP entre os per&#xED;odos pr&#xE9; e p&#xF3;s-tardio (8,33 (DP, 1,67) vs 7,63 (DP, 1,66) m/s; p &#x3C; 0,001) e entre os per&#xED;odos p&#xF3;s-imediato e p&#xF3;s-tardio (8,24 (DP, 1,78) vs 7,63 (DP, 1,66) m/s; p &#x3C; 0,001) (<xref ref-type="fig" rid="f5">Figura 2</xref>). Da mesma forma, a PP apresentou mudan&#xE7;as significativas entre os per&#xED;odos pr&#xE9; e p&#xF3;s-tardio (54,81 (DP, 18,73) mm Hg vs 48,52 (DP, 15,74) mm Hg; p &#x3C; 0,001) e entre os per&#xED;odos p&#xF3;s-imediato e p&#xF3;s-tardio (57,92 (DP, 16,21) mm Hg vs 48,52 (DP, 15,68) mm Hg; p &#x3C; 0,001) (<xref ref-type="fig" rid="f6">Figura 3</xref>).</p>
<fig id="f5">
<label>Figura 2</label>
<caption>
<title>Velocidade de onda de pulso nos per&#xED;odos pr&#xE9;, p&#xF3;s-imediato e p&#xF3;s-tardio. * p &#x3C; 0,05 entre pr&#xE9; e p&#xF3;s-imediato; # p &#x3C; 0,05 entre p&#xF3;s-imediato e p&#xF3;s-tardio.</title></caption>
<graphic xlink:href="0000-0000-abchf-001-01-0027-gf02-pt.tif"/></fig>
<fig id="f6">
<label>Figura 3</label>
<caption>
<title>Press&#xE3;o de pulso nos per&#xED;odos pr&#xE9;, p&#xF3;s-imediato e p&#xF3;s-tardio. * p &#x3C; 0,05 entre pr&#xE9; e p&#xF3;s-imediato; # p &#x3C; 0,05 entre p&#xF3;s-imediato e p&#xF3;s-tardio.</title></caption>
<graphic xlink:href="0000-0000-abchf-001-01-0027-gf03-pt.tif"/></fig>
</sec>
<sec sec-type="discussion">
<title>Discuss&#xE3;o</title>
<p>O presente estudo avaliou o efeito imediato e 1 hora ap&#xF3;s TMI nos &#xED;ndices hemodin&#xE2;micos de enchimento do VE, assim como nos &#xED;ndices hemodin&#xE2;micos puls&#xE1;teis em pacientes com ICFEp. O achado principal do presente estudo foi que o TMI modificou os &#xED;ndices hemodin&#xE2;micos de enchimento do VE e da hemodin&#xE2;mica puls&#xE1;til hemodin&#xE2;mica, demonstrando efeitos positivos da alta intensidade.</p>
<p>Houve um efeito significativo imediatamente ap&#xF3;s o TMI para E/e&#x2019;. Tamb&#xE9;m encontramos um efeito significativo do per&#xED;odo p&#xF3;s-imediato para o p&#xF3;s-tardio. Esses resultados confirmam nossa hip&#xF3;tese de que o TMI promoveria efeitos positivos sobre os &#xED;ndices hemodin&#xE2;micos de enchimento do VE. Algumas evid&#xEA;ncias sugerem que o TMI &#xE9; eficaz em modificar a raz&#xE3;o E/e&#x2019;, por&#xE9;m, quando realizado em uma intensidade de 30%.<xref ref-type="bibr" rid="B13"><sup>13</sup></xref> Contrariamente &#xE0; literatura, demonstramos que TMI de alta intensidade (80% da PIM) &#xE9; capaz de modificar os &#xED;ndices hemodin&#xE2;micos de enchimento do VE. Al&#xE9;m disso, vale mencionar que realizamos apenas 1 sess&#xE3;o de TMI supervisionado. Acreditamos que manter o TMI de alta intensidade por semanas pode promover a a&#xE7;&#xE3;o mec&#xE2;nica adequada nos m&#xFA;sculos respirat&#xF3;rios, facilitando o redirecionamento do fluxo sangu&#xED;neo perif&#xE9;rico, que pode gerar um est&#xED;mulo na biodisponibilidade do &#xF3;xido n&#xED;trico e consequentemente na vasodilata&#xE7;&#xE3;o.<xref ref-type="bibr" rid="B21"><sup>21</sup></xref></p>
<p>Com rela&#xE7;&#xE3;o &#xE0; VOP, observamos diferen&#xE7;as significativas na compara&#xE7;&#xE3;o entre os per&#xED;odos p&#xF3;s-imediato e p&#xF3;s-tardio. A VOP &#xE9; um importante preditor de doen&#xE7;a cardiovascular e mortalidade.<xref ref-type="bibr" rid="B22"><sup>22</sup></xref> Al&#xE9;m disso, estudos demonstram que a VOP est&#xE1; diretamente relacionada &#xE0; corre&#xE7;&#xE3;o do acoplamento ventr&#xED;culo-arterial, resultando em intoler&#xE2;ncia ao exerc&#xED;cio e causando altera&#xE7;&#xF5;es hemodin&#xE2;micas na p&#xF3;s-carga, com consequente aumento da dispneia aos esfor&#xE7;os pequenos e moderados.<xref ref-type="bibr" rid="B10"><sup>10</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B12"><sup>12</sup></xref> Embora os valores de VOP em nossa amostra estejam dentro da normalidade, a PP est&#xE1; elevada, identificando poss&#xED;vel rigidez a&#xF3;rtica e regurgita&#xE7;&#xE3;o para esses pacientes. Evid&#xEA;ncias indicam que um valor de 50 mm Hg para PP est&#xE1; relacionado a hipertrofia ventricular e mortalidade por doen&#xE7;as cardiovasculares.<xref ref-type="bibr" rid="B23"><sup>23</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref> No presente estudo, fomos capazes de demonstrar que houve uma redu&#xE7;&#xE3;o significativa da PP imediatamente ap&#xF3;s 1 sess&#xE3;o de TMI de alta intensidade (p = 0,023).</p>
<p>Outro resultado importante que observamos no presente estudo foi que 61,1% da amostra apresentou fraqueza muscular respirat&#xF3;ria, com ponto de corte de &#x3C; 80 cm H<sub>2</sub>0 para PIM.<xref ref-type="bibr" rid="B19"><sup>19</sup></xref> Sabemos que IMC &#x3E; 30 kg/m<sup>2</sup> observado para os presentes indiv&#xED;duos est&#xE1; diretamente relacionado &#xE0; redu&#xE7;&#xE3;o da PIM, devido &#xE0; distens&#xE3;o das fibras musculares do diafragma causada pela a&#xE7;&#xE3;o mec&#xE2;nica da gordura abdominal.<xref ref-type="bibr" rid="B25"><sup>25</sup></xref> Um menor IMC tamb&#xE9;m est&#xE1; associado a maior resist&#xEA;ncia dos m&#xFA;sculos respirat&#xF3;rios, demonstrando que a redu&#xE7;&#xE3;o da massa corporal &#xE9; fundamental para esses pacientes.<xref ref-type="bibr" rid="B26"><sup>26</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B27"><sup>27</sup></xref></p>
<p>&#xC9; importante reduzir os &#xED;ndices hemodin&#xE2;micos de enchimento do VE, a rigidez arterial e a PP, al&#xE9;m de aumentar a PIM nos pacientes com ICFEp, pois todos esses fatores est&#xE3;o integrados para o surgimento da dispneia e da fadiga durante esfor&#xE7;os.<xref ref-type="bibr" rid="B9"><sup>9</sup></xref> A redu&#xE7;&#xE3;o do desempenho desse sistema integrativo relacionado &#xE0; dispneia e &#xE0; fadiga pode ser explicada pela anormalidade na atividade quimiorreflexa, resultando assim em maior ventila&#xE7;&#xE3;o e maior atividade simp&#xE1;tica, dificultando ajustes barorreflexos arteriais e aumentando o tempo de vasoconstri&#xE7;&#xE3;o adren&#xE9;rgica, o que resulta em um aumento da pr&#xE9;-carga do ventr&#xED;culo direito.<xref ref-type="bibr" rid="B11"><sup>11</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B28"><sup>28</sup></xref> Essa hiperventila&#xE7;&#xE3;o inadequada durante o exerc&#xED;cio modula a atividade quimiorreflexa, devido a uma maior produ&#xE7;&#xE3;o de CO<sub>2</sub>, dificultando a extra&#xE7;&#xE3;o de O<sub>2</sub> perif&#xE9;rico e levando &#xE0; inefic&#xE1;cia do tamp&#xE3;o metab&#xF3;lico, possibilitando assim o aumento da atividade neuro-humoral.<xref ref-type="bibr" rid="B29"><sup>29</sup></xref> Por fim, podemos afirmar que a atividade metaborreflexa dos m&#xFA;sculos respirat&#xF3;rios tamb&#xE9;m influencia na resposta ventilat&#xF3;ria e na intoler&#xE2;ncia ao exerc&#xED;cio em pacientes com ICFEp. Essa sobrecarga metaborreflexa acarreta um aumento da atividade do nervo fr&#xEA;nico, e tamb&#xE9;m da atividade ventilat&#xF3;ria e simp&#xE1;tica, aumentando consequentemente a vasoconstri&#xE7;&#xE3;o e fadiga dos m&#xFA;sculos perif&#xE9;ricos.<xref ref-type="bibr" rid="B30"><sup>30</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B31"><sup>31</sup></xref></p>
<p>Entretanto, os processos de integra&#xE7;&#xE3;o relacionados a dispneia e a fadiga podem ter influ&#xEA;ncia direta no trabalho mioc&#xE1;rdico e redistribui&#xE7;&#xE3;o do fluxo sangu&#xED;neo.<xref ref-type="bibr" rid="B29"><sup>29</sup></xref> O TMI tem o potencial de reabilitar pacientes com ICFEp, e a justificativa est&#xE1; relacionada &#xE0; melhoria do retorno venoso, ao aumento do d&#xE9;bito card&#xED;aco, e &#xE0; redu&#xE7;&#xE3;o da pr&#xE9;-carga ventricular, independente do modo de treinamento.<xref ref-type="bibr" rid="B11"><sup>11</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B28"><sup>28</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B32"><sup>32</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B33"><sup>33</sup></xref> Al&#xE9;m disso, o TMI pode melhorar a capacidade funcional e consequentemente promover uma melhor qualidade de vida para esses pacientes, visto que dispneia e fadiga est&#xE3;o associadas a pior progn&#xF3;stico.</p>
<p>Os resultados do presente estudo s&#xE3;o importantes para levantar novas quest&#xF5;es sobre a intensidade do TMI, pois apenas 1 sess&#xE3;o com 80% de PIM promoveu melhorias significativas nos &#xED;ndices hemodin&#xE2;micos de enchimento do VE e na rigidez arterial, sem complica&#xE7;&#xF5;es durante o protocolo. Portanto, nossos resultados demonstram que 1 sess&#xE3;o de TMI de alta intensidade &#xE9; eficaz na melhoria dos par&#xE2;metros avaliados em pacientes com ICFEp. Entretanto, vale mencionar que o TMI de alta intensidade parece ser uma estrat&#xE9;gia promissora no cen&#xE1;rio da reabilita&#xE7;&#xE3;o.</p>
</sec>
<sec>
<title>Limita&#xE7;&#xE3;o</title>
<p>O presente estudo tem algumas limita&#xE7;&#xF5;es, entre as quais podemos mencionar a aus&#xEA;ncia de um grupo controle, que acrescentaria informa&#xE7;&#xF5;es importantes sobre os efeitos do TMI. Outra limita&#xE7;&#xE3;o &#xE9; o fato de que realizamos apenas 1 sess&#xE3;o de TMI, causando uma lacuna na literatura sobre os efeitos cr&#xF4;nicos do TMI de alta intensidade. Por fim, enfatizamos a import&#xE2;ncia da pesquisa na &#xE1;rea do TMI para pacientes com ICFEp. Aqui, sugerimos que estudos futuros avaliem os efeitos de diferentes intensidades de TMI com compara&#xE7;&#xF5;es em rela&#xE7;&#xE3;o a um grupo controle.</p>
</sec>
<sec sec-type="conclusions">
<title>Conclus&#xE3;o</title>
<p>Nossos resultados demonstraram que uma &#xFA;nica sess&#xE3;o de TMI de alta intensidade melhorou os &#xED;ndices hemodin&#xE2;micos de enchimento do VE e a rigidez arterial em pacientes com ICFEp. Estudos futuros devem testar sess&#xF5;es consecutivas de TMI de alta intensidade como m&#xE9;todo de reabilita&#xE7;&#xE3;o de pacientes com ICFEp.</p>
</sec></body>
<back>
<fn-group>
<fn fn-type="other" id="fn4">
<p><bold>Aprova&#xE7;&#xE3;o &#xE9;tica e consentimento informado</bold></p>
<p>Este estudo foi aprovado pelo Comit&#xEA; de &#xC9;tica da Universidade Luterana do Brasil sob o n&#xFA;mero de protocolo 393386.14.1.0000.5349. Todos os procedimentos envolvidos nesse estudo est&#xE3;o de acordo com a Declara&#xE7;&#xE3;o de Helsinki de 1975, atualizada em 2013. O consentimento informado foi obtido de todos os participantes inclu&#xED;dos no estudo.</p></fn>
<fn fn-type="supported-by" id="fn5">
<p><bold>Fontes de financiamento</bold></p>
<p>O presente estudo n&#xE3;o teve fontes de financiamento externas.</p></fn>
<fn fn-type="other" id="fn6">
<p><bold>Vincula&#xE7;&#xE3;o acad&#xEA;mica</bold></p>
<p>N&#xE3;o h&#xE1; vincula&#xE7;&#xE3;o deste estudo a programas de p&#xF3;s-gradua&#xE7;&#xE3;o.</p></fn></fn-group>
</back></sub-article>
</article>
